

**STUDI BIOINFORMATIKA VARIASI DAN
EKSPRESI GEN YANG BERHUBUNGAN DENGAN
*TAKAYASU ARTERITIS (TA)***

SKRIPSI

Disusun Untuk Memenuhi Sebagian Persyaratan
Mencapai Derajat Sarjana Farmasi



Disusun Oleh :

Nabila Aulia Rahma
NIM : 202205046

**PROGRAM STUDI FARMASI PROGRAM SARJANA
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH GOMBONG
GOMBONG**

2026

**STUDI BIOINFORMATIKA VARIASI DAN EKSPRESI
GEN YANG BERHUBUNGAN DENGAN *TAKAYASU*
ARTERITIS (TA)**

SKRIPSI

Disusun Untuk Memenuhi Sebagian Persyaratan
Mencapai Derajat Sarjana Farmasi



Disusun Oleh :

Nabila Aulia Rahma
NIM : 202205046

**PROGRAM STUDI FARMASI PROGRAM SARJANA
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH GOMBONG
GOMBONG
2026**

HALAMAN PERSETUJUAN
STUDI BIOINFORMATIKA VARIASI DAN EKSPRESI GEN YANG
BERHUBUNGAN DENGAN *TAKAYASU ARTERITIS* (TA)

Telah disetujui dan dinyatakan Telah memenuhi syarat untuk diujikan
Pada Tanggal 26 Mei 2026

Yang dipersiapkan dan disusun oleh :

Nabila Aulia Rahma

NIM: 202205046

Susunan Tim Pembimbing

apt. Dwiki Fitri, M.Farm

(.....)

Mengetahui

Ketua Program Studi Farmasi Program Sarjana
Universitas Muhammadiyah Gombong



apt. Tri Cahyani Widiastuti, M.Sc

NIDN : 616028901

HALAMAN PENGESAHAN
STUDI BIOINFORMATIKA VARIASI DAN EKSPRESI GEN YANG
BERHUBUNGAN DENGAN *TAKAYASU ARTERITIS* (TA)


Yang dipersiapkan dan disusun oleh :

Nabila Aulia Rahma

NIM : 202205046

Telah dipertahankan di hadapan Tim Penguji
pada tanggal 26 Mei 2026

Susunan Tim Penguji

1. Dr. apt. Muh Husnul Khuluq, M.Farm (.....)
2. apt. Wahyu Rahmatulloh, M.Farm (.....)
3. apt. Dwiki Fitri, M.Farm (.....)

Mengetahui

Ketua Program Studi Farmasi Program Sarjana
Universitas Muhammadiyah Gombong



apt. Tri Cahyani Widiastuti, M.Sc

NIDN : 616028901

HALAMAN PERNYATAAN

Dengan ini saya menyatakan bahwa dalam skripsi yang saya ajukan tidak terdapat karya yang pernah diajukan untuk memperoleh gelar kesarjanaan di suatu Perguruan Tinggi, dan sepanjang pengetahuan saya juga tidak terdapat karya atau pendapat yang pernah ditulis atau diterbitkan oleh orang lain, kecuali secara tertulis digunakan sebagai rujukan dalam naskah ini dan disebutkan dalam daftar pustaka dan sudah dinyatakan lolos uji plagiarisme. Apabila dikemudian hari diketemukan seluruh atau sebagian dari skripsi tersebut terdapat indikasi plagiarisme, saya bersedia menerima sanksi sesuai peraturan perundang-undangan yang berlaku.

Demikianlah pernyataan ini dibuat dalam keadaan sadar dan tanpa unsur paksaan dari siapapun.

Gombong, Tanggal 13 Bulan Januari 2026



Nabila Aulia Rahma

PERNYATAAN BEBAS PLAGIARISME

Saya yang bertanda tangan dibawah ini

Nama : Nabila Aulia Rahma
Tempat, tanggal lahir : Tangerang, 16 Oktober 2003
Alamat : Jl. Raden Saleh, RT001/RW003, Karang Tengah,
Tangerang
Nomor telp/hp : 085719823676
Alamat email : nabelaaaw1610@gmail.com

Dengan ini menyatakan dengan sesungguhnya bahwa skripsi saya yang berjudul :

**Studi Bioinformatika Variasi dan Ekspresi Gen Yang Berhubungan
Dengan *Takayasu Arteritis* (TA)**

Bebas dari plagiarisme dan bukan hasil karya orang lain.

Apabila dikemudian hari ditemukan seluruh atau sebagian dari skripsi tersebut terdapat indikasi plagiarisme, saya bersedia menerima sanksi sesuai peraturan perundang-undangan yang berlaku.

Demikian surat pernyataan ini dibuat dalam keadaan tanpa unsur paksaan dari siapapun.

Gombong, 13 Januari 2026

Yang menyatakan



Nabila Aulia Rahma

**HALAMAN PERNYATAAN PERSETUJUAN PUBLIKASI TUGAS
AKHIR UNTUK KEPENTINGAN AKADEMIS**

Sebagai civitas akademis Universitas Muhammadiyah Gombong, saya yang bertanda dibawah ini :

Nama : Nabila Aulia Rahma
NIM : 202205046
Program studi : Farmasi Program Sarjana
Jenis karya : Skripsi

Demi pengembangan ilmu pengetahuan, menyetujui untuk memberikan kepada Universitas Muhammadiyah Gombong. **Hak Bebas Royalti Noneksklusif** (*Non-exclusive Royalty-Free Right*) atas skripsi saya yang berjudul :

**Studi Bioinformatika Variasi dan Ekspresi Gen Yang Berhubungan Dengan
*Takayasu Arteritis (TA)***

Beserta perangkat yang ada (jika diperlukan). Dengan Hak Bebas Royalti Noneksklusif ini Universitas Muhammadiyah Gombong berhak menyimpan, mengalihk/formatkan, mengelola dalam bentuk pangkalan data, merawat dan mempublikasikan tugas akhir saya selama mencantumkan nama saya sebagai penulis/pencipta dan sebagai pemilik Hak Cipta. Demikian pernyataan ini saya buat dengan sebenarnya.

Gombong, 13 Januari 2026

Yang menyatakan



Nabila Aulia Rahma

KATA PENGANTAR




Puji dan syukur penulis panjatkan atas kehadiran Allah SWT yang telah memberikan rahmat dan hidayah-Nya, sehingga penulis dapat menyelesaikan skripsi dengan judul “Studi Bioinformatika Variasi dan Ekspresi Gen Yang Berhubungan Dengan *Takayasu Arteritis* (TA)”. Skripsi ini disusun untuk memenuhi salah satu persyaratan meraih gelar sarjana farmasi di Universitas Muhammadiyah Gombong.

Dalam penyelesaian studi dan penulisan skripsi ini, penulis banyak memperoleh bantuan baik pengajaran, bimbingan dan arahan dari berbagai pihak baik secara langsung maupun tidak langsung. Untuk itu penulis mengucapkan banyak terima kasih kepada :

1. Prof. Dr. Sofyan Anif, M.Si selaku Rektor Universitas Muhammadiyah Gombong.
2. Ns. Diah Astutiningrum, S.Kep., M.Kep selaku Dekan Fakultas Ilmu Kesehatan Universitas Muhammadiyah Gombong.
3. apt. Tri Cahyani Widiastuti, M.Sc. selaku Ketua Program Studi Farmasi Program Sarjana Universitas Muhammadiyah Gombong.
4. apt. Dwiki Fitri, M.Farm selaku Dosen Pembimbing yang telah meluangkan waktu, tenaga dan pemikiran dalam membimbing penulis selama proses penyelesaian skripsi ini. Tanpa arahan dan saran berharga dari beliau, penelitian ini tidak akan tersusun dengan baik.
5. Dr. apt. Muh Husnul Khuluq, M.Farm selaku Dosen Penguji pertama yang telah meluangkan waktu, pemikiran dan memberi arahan dalam proses penyusunan skripsi ini.
6. apt. Wahyu Rahmatulloh, M.Farm selaku Dosen Penguji kedua yang telah meluangkan waktu, pemikiran dan memberi arahan dalam proses penyusunan skripsi ini.

7. apt. Ayu Nissa Ainni, M.Farm selaku Dosen Wali yang telah memberi nasihat dan membimbing penulis selama menjalani studi di Universitas Muhammadiyah Gombong.
8. Seluruh Staf Dosen Program Studi Farmasi Program Sarjana Universitas Muhammadiyah Gombong yang telah memberikan ilmu serta wawasannya kepada penulis.
9. Seluruh Staf Sekretariat Program Studi Farmasi Program Sarjana Universitas Muhammadiyah Gombong yang telah membantu dan memberikan berbagai informasi terkait kebutuhan dalam penyusunan skripsi ini.
10. Kepada semua orang yang sudah banyak membantu penulis dalam menyelesaikan skripsi ini, yang tidak dapat penulis sebutkan satu persatu. Semoga Allah SWT membalas semua kebaikan kalian. Aamiin Allahumma Aamiin.

Gombong, 13 Januari 2026


Nabila Aulia Rahma
NIM. 202205046

HALAMAN PERSEMBAHAN

Alhamdulillah, puji dan syukur penulis panjatkan kehadiran Allah SWT yang senantiasa memberikan kemudahan, kelancaran dan keberkahan bagi penulis untuk menyelesaikan tugas akhir yaitu skripsi. Skripsi ini merupakan persembahan kecil tanda cinta dan terima kasih yang saya berikan untuk orang-orang yang telah membuat hidup saya berharga dan bermakna. Saya persembahkan kepada :

1. Kedua Orang Tua yang sangat saya sayang dan banggakan yang selalu tulus mendo'akan, memberikan nasihat dan semangat terbaik tiada henti-hentinya. Ayah dan Ibu yang selalu membukakan tangan dan bahunya serta banyak memberikan moral maupun material. Saya ucapkan terima kasih yang sebanyak-banyaknya atas pengorbanan serta kasih sayang, ridho dan do'a untuk saya menjadi semangat melakukan yang terbaik.
2. Adikku yang telah memberikan banyak sekali dukungan serta semangat terbaik kepada saya.
3. Pemilik NIM 221030790467 terima kasih yang tulus saya sampaikan karena telah menjadi teman setia selama 17 tahun. Kebersamaan ini adalah anugerah berharga yang selalu memberi semangat, tawa, dan kekuatan dalam setiap langkah. Semoga persahabatan yang indah ini senantiasa terjaga sampai kapan pun.
4. Bioinfogen *squad* yang telah memberikan begitu banyak bantuan, dukungan dan semangat. Kehangatan serta kebersamaan yang tercipta menjadi sumber motivasi berharga dalam proses penyusunan skripsi ini.
5. Teman-teman cantikku calon pengusaha sukses tsafna, inaya, vicka, iska, vina yang senantiasa hadir memberikan semangat, dukungan dan kebersamaan. Perjalanan ini terasa lebih ringan dan bermakna karena kita saling menguatkan dalam suka maupun duka.
6. Teman-teman angkatan 2022 Program Studi Farmasi Program Sarjana.
7. Untuk diri saya sendiri Nabila Aulia Rahma yang telah berusaha sekuat tenaga, tetap bertahan dan tidak menyerah dalam setiap proses, hingga akhirnya skripsi

ini dapat terselesaikan. Semoga kerja keras dan do'a yang tercurah dapat menjadi pijakan untuk langkah yang lebih baik kedepannya.

8. Terakhir pada semua pihak yang terlibat dalam proses penyusunan skripsi ini.



PROGRAM STUDI FARMASI PROGRAM SARJANA
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH GOMBONG
Skripsi, Mei 2026

Nabila Aulia Rahma¹⁾, Dwiki Fitri²⁾

ABSTRAK

STUDI BIOINFORMATIKA VARIASI DAN EKSPRESI GEN YANG BERHUBUNGAN DENGAN *TAKAYASU ARTERITIS* (TA)

Latar Belakang: *Takayasu Arteritis* (TA) merupakan penyakit inflamasi kronis idiopatik yang menyerang pembuluh darah besar. Faktor genetik berperan penting dalam patogenesis penyakit TA, namun penelitian bioinformatika terkait variasi dan ekspresi gen pada TA masih terbatas.

Tujuan Penelitian: Penelitian ini bertujuan untuk mengidentifikasi gen risiko TA berdasarkan data genomik serta menganalisis hubungan variasi dengan ekspresi gen pada jaringan tubuh manusia.

Metode Penelitian: Penelitian ini menggunakan pendekatan bioinformatika dengan data sekunder dari *GWAS Catalog*, *HaploReg v4.2*, *GTEEx Portal*, dan *Ensembl Genome Browser*. SNP diseleksi berdasarkan nilai $p\text{-value} < 5 \times 10^{-8}$, kemudian dianalisis untuk mengidentifikasi variasi *missense*, pola ekspresi gen, dan distribusi frekuensi alel.

Hasil Penelitian: Sebanyak 166 SNP teridentifikasi berkaitan dengan TA, dengan 68 SNP memenuhi ambang signifikansi genomik. Enam SNP teridentifikasi sebagai variasi *missense*, yaitu rs3130618 (GPANK1), rs1576 (CCHCR1), rs9267532 (LY6G5B), rs10885 (PRRC2A), rs9267547 (LY6G6F), dan rs45479291 (HLA-V), dengan pola ekspresi yang relevan pada jaringan arteri, *whole blood*, paru-paru, dan testis.

Kesimpulan: Keenam gen kandidat yang teridentifikasi berpotensi berkontribusi terhadap patofisiologi TA melalui pola ekspresi gen pada berbagai jaringan tubuh.

Rekomendasi: Gen kandidat perlu dikembangkan sebagai biomarker *Takayasu Arteritis*, namun masih diperlukan penelitian lanjutan dengan populasi yang lebih luas untuk validasi hasil.

Kata Kunci;

Takayasu Arteritis, Bioinformatika, GWAS Catalog

¹ Mahasiswa, Universitas Muhammadiyah Gombong

² Dosen, Universitas Muhammadiyah Gombong

ABSTRACT

BIOINFORMATIC STUDY OF GENE VARIATIONS AND EXPRESSION ASSOCIATED WITH *TAKAYASU ARTERITIS* (TA)

Background: *Takayasu Arteritis* (TA) is a chronic idiopathic inflammatory disease affecting the large blood vessels. Genetic factors play an important role in the pathogenesis of TA, however bioinformatics research on gene variations and expression in TA remains limited.

Purpose: This study aimed to identify TA risk genes based on genomic data and to analyse the relationship between genetic variations and gene expression across human tissues.

Method: This study employed a bioinformatics approach using secondary data from the GWAS Catalog, *HaploReg* v4.2, *GTEx Portal*, and *Ensembl Genome Browser*. SNPs were selected based on a p-value threshold of $< 5 \times 10^{-8}$ and further analysed to identify missense variants, gene expression patterns, and allele frequency distributions.

Result: A total of 166 SNPs were identified as associated with TA, of which 68 SNPs met the genome-wide significance threshold. Six SNPs were identified as missense variants, namely rs313618 (GPANK1), rs1576 (CCHCR1), rs9267532 (LY6G5B), rs10885 (PRRC2A), rs9267547 (LY6G6F), and rs45479291 (HLA-V), with relevant expression patterns observed in arterial tissue, whole blood, lung, and testis.

Conclusion: The six identified candidate genes potentially contribute to the pathophysiology of TA through tissue-specific gene expression patterns.

Recommendation: Candidate genes need to be developed as biomarkers for *Takayasu Arteritis*, however further studies with larger populations are still needed to validate the findings.

Keywords;

Takayasu Arteritis, Bioinformatics, GWAS Catalog

¹ Student of Universitas Muhammadiyah Gombong

² Lecturer of Universitas Muhammadiyah Gombong

DAFTAR ISI

HALAMAN JUDUL	i
HALAMAN PERSETUJUAN	ii
HALAMAN PENGESAHAN	iii
HALAMAN PERNYATAAN.....	iv
PERNYATAAN BEBAS PLAGIARISME.....	v
HALAMAN PERNYATAAN PERSETUJUAN PUBLIKASI	vi
KATA PENGANTAR.....	vii
HALAMAN PERSEMBAHAN	ix
ABSTRAK	xi
ABSTRACT	xii
DAFTAR ISI.....	xiii
DAFTAR TABEL	xv
DAFTAR GAMBAR	xvi
DAFTAR BAGAN.....	xvii
DAFTAR LAMPIRAN	xviii
DAFTAR SINGKATAN.....	xix
BAB I PENDAHULUAN.....	1
1.1 Latar Belakang	1
1.2 Rumusan Masalah	3
1.3 Tujuan Penelitian.....	4
1.4 Manfaat Penelitian.....	4
1.5 Keaslian Penelitian	5
BAB II TINJAUAN PUSTAKA	8
2.1 Tinjauan Teori.....	8
2.2 Kerangka Teori	26
2.3 Kerangka Konsep	27
2.4 Keterangan Empiris	28
BAB III METODOLOGI PENELITIAN	29
3.1 Desain atau Rancangan Penelitian.....	29

3.2 Sumber Data Penelitian	29
3.3 Tempat dan Waktu Penelitian	30
3.4 Definisi Operasional	30
3.5 Instrumen Penelitian	31
3.6 Teknik Analisis Data	31
BAB IV HASIL DAN PEMBAHASAN	33
4.1 Hasil Penelitian	33
4.2 Pembahasan Penelitian	42
4.3 Keterbatasan Penelitian	58
BAB V KESIMPULAN DAN SARAN	59
5.1 Kesimpulan	59
5.2 Saran	59
DAFTAR PUSTAKA	
LAMPIRAN	

DAFTAR TABEL

Tabel 1. 1 Keaslian Penelitian	5
Tabel 3. 1 Definisi Operasional	30
Tabel 4. 1 Hasil Penelusuran dari Katalog GWAS	33
Tabel 4. 2 SNP pada TA dengan p-value $< 5 \times 10^{-8}$ dan Tervalidasi Missense.....	34
Tabel 4. 3 Ekspresi Gen yang Dominan pada Jaringan Manusia Penyebab TA...	35
Tabel 4. 4 Frekuensi Alel pada Setiap SNP	40



DAFTAR GAMBAR

Gambar 2. 1	Fase aktif TA pada aorta torakalis desenden.....	11
Gambar 2. 2	Fase penyembuhan TA pada aorta torakalis desenden.....	12
Gambar 2. 3	Patofisiologi TA	13
Gambar 2. 4	Hasil CTA pada wanita berusia 66 tahun yang mengalami TA	16
Gambar 2. 5	Klasifikasi TA	17
Gambar 4. 1	Ekspresi SNP Alel Kerentanan Penyakit Takayasu Arteritis (TA)..	36
Gambar 4. 2	Ekspresi Gen GPANK1	37
Gambar 4. 3	Ekspresi Gen CCHCR1	37
Gambar 4. 4	Ekspresi Gen LY6G5B	38
Gambar 4. 5	Ekspresi Gen PRRC2A.....	38
Gambar 4. 6	Ekspresi Gen LY6G6F	39
Gambar 4. 7	Ekspresi Gen HLA-V	39
Gambar 4. 8	Distribusi Frekuensi Alel	41

DAFTAR BAGAN

Bagan 2. 1 Kerangka Teori.....	26
Bagan 2. 2 Kerangka Konsep	27



DAFTAR LAMPIRAN

Lampiran 1. Lembar Bimbingan Proposal

Lampiran 2. Lembar Bimbingan Hasil

Lampiran 3. Lembar Bimbingan Abstrak

Lampiran 4. Surat Pernyataan Tidak Melakukan Etik Penelitian


Lampiran 5. Surat Pernyataan Bebas Plagiarisme

Lampiran 6. Hasil Analisis SNP pada Basis Data Katalog GWAS

Lampiran 7. Hasil Analisis Basis Data HaploReg Versi 4.2

Lampiran 8. Hasil Analisis Basis Data GTEx Portal

Lampiran 9. Hasil Analisis Basis Data Ensembl Genome Browser



DAFTAR SINGKATAN

TA.	<i>Takayasu Arteritis</i>
GWAS.	<i>Genome Wide Association</i>
GTE _x .	<i>Genome-Tissue Expression</i>
SNP.	<i>Single Nucleotide Polymorphisms</i>
HaploReg V4.2.	<i>HaploReg Versi 4.2</i>
eQTL.	<i>Expression Quantitative Trait Loci</i>
cis-eQTL.	<i>cis-Expression Quantitative Trait Loci</i>
AFR.	<i>Africa</i>
AMR.	<i>America</i>
EUR.	<i>Europe</i>
SAS.	<i>South Asia Summit</i>
EAS.	<i>East Asia Summit</i>
RNA.	<i>Ribonucleic Acid</i>
DNA.	<i>Deoxyribonucleic Acid</i>
NK.	<i>Natural Killer</i>
HLA.	<i>Human Leukocyte Antigen</i>
MHC.	<i>Major Histocompatibility Complex</i>
GPANK1.	<i>G-Patch Domain Ankyrin Repeats 1</i>
CCHCR1.	<i>Coiled-Coil alpha-Helical Rod protein 1</i>
PRRC2A.	<i>Proline Rich Coiled-Coil 2A</i>
LY6G6F.	<i>Lymphocyte antigen 6 family member G6F</i>
LY6G5B.	<i>Lymphocyte antigen 6 family member G5B</i>
HLA-V.	<i>Human Leukocyte Antigen V</i>
NES.	<i>Normalized Effect Size</i>
CC.	<i>Cytosine Cytosine</i>
TT.	<i>Thymine Thymine</i>
AA.	<i>Adenine Adenine</i>
GG.	<i>Guanine Guanine</i>
CA.	<i>Cytosine Adenine</i>
GA.	<i>Guanine Adenine</i>
GC.	<i>Guanine Cytosine</i>

CT.	<i>Cytosine Thymine</i>
mRNA.	<i>messenger Ribonucleic Acid</i>
DbSNP func annot.	<i>Database of Single Nucleotide Polymorphisms Functional Annotation</i>
Ref.	<i>Reference Allele</i>
Alt.	<i>Alternative Allele</i>
OFD1.	<i>Oral Facial Digital Syndrome 1</i>
PCM1.	<i>Pericentriolar Materials 1</i>
Lcn.	<i>Lipocalin</i>
TNF.	<i>Tumor Necrosis Factor</i>
ITGAM.	<i>Intergrin Subunit Alpha M</i>
GCA.	<i>Giant Cell Arteritis</i>
ADAM3	<i>A Disintegrin And Metalloprotease 3</i>
NMOSD.	<i>Neuromyelitis Optica Spectrum Disorder</i>
MS.	<i>Multiple Sclerosis</i>
TAP1.	<i>Transporter Associated with Antigen Processing 1</i>
TAP2.	<i>Transporter Associated with Antigen Processing 2</i>
LD.	<i>Linkage Disequilibrium</i>

BAB I

PENDAHULUAN

1.1 Latar Belakang

Pengembangan teknologi yang pesat saat ini sangat membantu dalam mengidentifikasi kerentanan genomik, terutama dalam mendeteksi variasi gen. Variasi gen yang berperan penting pada terjadinya kesalahan urutan pada struktur DNA yang tersusun atas basa nukleotida A, T, G, dan C (Astuti *et al.*, 2023). *Takayasu Arteritis* (TA) merupakan suatu penyakit genetik yang disebabkan inflamasi kronis yang progresif dan penyebab aslinya belum diketahui secara pasti (idiopatik). Penyakit TA ini menyebabkan penyempitan pada pembuluh darah, oklusi (pembuluh darah tertutup total, sehingga aliran darah sempit), serta aneurisma (dinding pembuluh darah menjadi lemah dan menonjol) (Satriyanto, 2020). TA juga dikenal sebagai *pulseless disease*, *aortic arch syndrome*, dan *occlusive thromboaropathy* (Wira Pratama Yasa *et al.*, 2022).

Prevalensi TA di dunia mencapai 2,6 juta kasus per tahun yang banyak ditemukan di Jepang, Asia Tenggara, India, dan Amerika Selatan (Febrina, 2015). TA sering dialami oleh wanita muda berusia < 40 tahun, dengan rasio wanita terhadap pria sebesar 5-12:1 (Liu *et al.*, 2022). Tingkat kejadian TA di Amerika Serikat dilaporkan sebesar 0,9 kasus per 1 juta penduduk, sementara di Eropa berkisar antara 0,4-1,5 kasus per 1 juta penduduk (Chair *et al.*, 2018). Data mengenai TA di Benua Afrika masih terbatas. Akan tetapi, terdapat suatu studi terbesar di Afrika Selatan tepatnya di Rumah Sakit Groote Schuur, Provinsi Western Cape, dimana berdasarkan penelitian tersebut diketahui terdapat sebanyak 272 pasien yang mengalami TA (Botha, 2023). Angka kejadian TA di Indonesia juga masih jarang terjadi, namun di Pasuruan, Jawa Timur ditemukan pasien wanita berusia 18 tahun yang didiagnosis menderita TA (Lusida *et al.*, 2020).

Gejala TA secara klinis dibedakan menjadi dua fase utama, yaitu fase awal dan fase stenosis. Fase awal ditandai oleh gejala umum yang tidak

spesifik seperti demam, rasa lelah, dan nyeri kepala, sedangkan gejala untuk fase stenosis ditandai oleh hipertensi, klaudikasio, bradikardi, *bruit*, serta angina (Rajlawot *et al.*, 2022). Faktor risiko penyakit kardiovaskular sendiri terdapat pada pasien dengan hipertensi arteri, hiperlipidemia, serta kebiasaan merokok (Laurent *et al.*, 2021). Penyebab pasti TA hingga kini belum diketahui, namun terdapat bukti ilmiah yang menunjukkan bahwa faktor genetik berperan penting dalam patogenesis penyakit ini. Sejumlah studi genomik, khususnya yang menggunakan pendekatan *Genome-Wide Association Study* (GWAS), telah berhasil mengidentifikasi sejumlah gen yang berpotensi dalam penyakit TA. Penelitian tersebut menunjukkan bahwa alel HLA-B*52:01 muncul sebagai penanda genetik paling kuat pada berbagai populasi (Ortiz-Fernández, 2021a).

Pemanfaatan basis data genomik menjadi salah satu pendekatan utama dalam mengidentifikasi hubungan antara gen dengan mekanisme suatu penyakit. Terdapat berbagai basis data yang memuat informasi mengenai keterkaitan antara gen dengan proses patogenesis suatu penyakit, salah satunya adalah katalog GWAS. Basis data ini berisi variasi genetik yang menghubungkan keseluruhan genom dengan fenotip yang dipetakan melalui *cis-expression quantitative trait loci* (cis-eQTL), yang berperan dalam memengaruhi karakteristik fenotip alami (Medi Sushanti *et al.*, 2023). Katalog GWAS juga berfungsi untuk mengidentifikasi varian yang berasosiasi dengan penyakit umum pada populasi, yang secara akumulatif dapat berkontribusi terhadap mekanisme patogenesis penyakit seperti TA. Basis data lain yang digunakan yaitu *HaploReg* versi (4.2), *GTEx Portal*, dan *Ensembl genome browser 115*.

Al-Qur'an merupakan kitab suci umat islam yang diturunkan Allah SWT kepada Nabi Muhammad SAW, juga mengandung isyarat yang dapat dikaitkan dengan ilmu genetika. Salah satu ayat Al-Qur'an, menafsirkan terkait silsilah manusia yaitu berasal dari Nabi Adam AS dan Hawa. Hal ini dibuktikan dengan kesamaan ciri fisik manusia di bumi sebagai keturunan

mereka, serta proses penciptaan manusia dari setetes air mani yang kemudian berkembang dan menyebar ke seluruh penjuru dunia (Fadly *et al.*, 2023). Ayat yang dikaitkan dengan ilmu genetika tersebut terdapat dalam surah An-Nisa' ayat 1, yang berbunyi :

يَا أَيُّهَا النَّاسُ اتَّقُوا رَبَّكُمُ الَّذِي خَلَقَكُمْ مِنْ نَفْسٍ وَاحِدَةٍ وَخَلَقَ مِنْهَا زَوْجَهَا وَبَثَّ مِنْهُمَا رِجَالًا كَثِيرًا وَنِسَاءً ۚ وَاتَّقُوا اللَّهَ الَّذِي تَسَاءَلُونَ بِهِ وَالْأَرْحَامَ ۚ إِنَّ اللَّهَ كَانَ عَلَيْكُمْ رَقِيبًا

Artinya :

“Wahai manusia, bertakwalah kepada Tuhanmu yang telah menciptakanmu dari diri yang satu (Adam) dan dia menciptakan darinya pasangan (Hawa). Dari keduanya Allah memperkembangbiakkan laki-laki dan perempuan yang banyak. Bertakwalah kepada Allah yang dengan nama-Nya kamu saling meminta dan (peliharalah) hubungan kekeluargaan. Sesungguhnya Allah selalu menjaga dan mengawasimu”.

Berdasarkan penjelasan diatas, penelitian bioinformatika mengenai variasi dan ekspresi gen yang berkaitan dengan TA masih sangat terbatas, terutama penelitian yang memanfaatkan data dari katalog GWAS. Studi lanjutan berbasis data genomik diperlukan untuk menelusuri variasi dan ekspresi gen secara lebih spesifik. Pendekatan ini dinilai efisien dari segi waktu dan biaya serta berpotensi mengungkap gen risiko baru yang dapat memperdalam pemahaman terkait mekanisme molekuler TA.

1.2 Rumusan Masalah

Perumusan masalah berikut dapat dibuat berdasarkan latar belakang yang telah diuraikan, yaitu :

- 1.2.1 Apa saja gen yang berpotensi berperan dalam risiko terjadinya penyakit *Takayasu Arteritis* (TA) berdasarkan hasil penelitian pada basis data katalog GWAS dengan nilai $p\text{-value} < 5 \times 10^{-8}$?
- 1.2.2 Apakah terdapat hubungan antara variasi gen dengan ekspresi gen yang teridentifikasi melalui basis data *GTEx Portal*?

1.3 Tujuan Penelitian

1.3.1 Tujuan Umum

Penelitian ini bertujuan untuk mengidentifikasi variasi gen yang berkaitan dengan TA serta menganalisis hubungan antara variasi dan ekspresi gen melalui pemanfaatan basis data dengan Metode Bioinformatika.

1.3.2 Tujuan Khusus

- 1.3.2.1 Mengetahui gen berisiko pada penyakit TA yang ditemukan dalam basis data dengan pendekatan bioinformatika.
- 1.3.2.2 Mengetahui hubungan antara variasi gen dengan tingkat ekspresi gen yang ditemukan pada jaringan tertentu.

1.4 Manfaat Penelitian

1.4.1 Manfaat Bagi Pengembangan Ilmu

Bagi pengembangan ilmu, penelitian ini berpotensi memperkaya pengetahuan ilmiah dibidang bioinformatika, terutama dalam pemanfaatan data genetik untuk mengidentifikasi gen-gen yang berperan dalam penyakit TA.

1.4.2 Manfaat Bagi Praktisi

Bagi praktisi, hasil penelitian ini dapat memberikan wawasan baru mengenai gen-gen yang berkontribusi terhadap risiko TA, sehingga dapat dijadikan referensi maupun literatur pertimbangan dalam penemuan variasi gen menggunakan pendekatan bioinformatika.

1.4.3 Manfaat Bagi Masyarakat

Penelitian ini diharapkan mampu meningkatkan pemahaman masyarakat mengenai peran faktor genetik pada TA.

1.4.4 Manfaat Bagi Peneliti

Kegiatan ini menjadi sarana pengembangan kompetensi dalam analisis data bioinformatika serta memberikan pengalaman dalam mengintegrasikan variasi genetik untuk mengidentifikasi hubungan antara variasi dan ekspresi gen pada TA.

1.5 Keaslian Penelitian


Keaslian penelitian ini disusun dengan merujuk pada sejumlah studi terdahulu yang memiliki keterkaitan topik dengan penelitian yang dilakukan. Meskipun demikian, penelitian-penelitian tersebut menunjukkan perbedaan pada aspek karakteristik subjek, jumlah dan penempatan variabel penelitian, serta pendekatan analisis yang digunakan.

Tabel 1. 1 Keaslian Penelitian

Nama, Peneliti, Tahun	Judul Penelitian	Metode Penelitian	Hasil Penelitian	Perbedaan dan Persamaan Penelitian
(Fitri <i>et al.</i> , 2024)	Integrasi basis data genomik dan bioinformatika untuk mengidentifikasi varian seluruh genom pada penyakit genom pada penyakit <i>myasthenia gravis</i> di berbagai benua.	Pendekatan bioinformatika	Hasil penelitian ini yaitu ditemukan dua varian utama (rs2071591 dan rs231770) yang memengaruhi aktivitas gen LTA di jaringan otak dan gen CTLA4 di jaringan testis.	Persamaan : metode yang digunakan Perbedaan ; jenis penyakit

Nama, Peneliti, Tahun	Judul Penelitian	Metode Penelitian	Hasil Penelitian	Perbedaan dan Persamaan Penelitian
(Huang <i>et al.</i> , 2018)	Analisis Bioinformatika Mengidentifikasi Tiga Gen yang Berpotensi Penting dan Terekspresi Berbeda pada Sel Mononuklear Darah Perifer Pasien dengan Arteritis Takayasu	Pendekatan bioinformatika	Ditemukan 932 gen terekspresi berbeda, terdiri dari 372 meningkat dan 560 menurun. Analisis jaringan protein menunjukkan empat gen utama (RHOA, FOS, EGR1, dan GNB1) sebagai gen sentral yang berpotensi berperan dalam patogenesis TA.	Persamaan : jenis penyakit Perbedaan : Metode yang digunakan - Menggunakan analisis ekspresi gen <i>Whole Human Genome Microarray</i> - Data ekspresi gen diunduh dari basis data <i>Gene Expression Omnibus (GEO)</i>
(Terao, 2018)	Determinasi Genetik dan Epistasis LILRA3 dan HLA-B*52 pada Arteritis Takayasu	Pendekatan bioinformatika	Hasil penelitian ini yaitu ditemukan empat lokus genetik baru yang terkait dengan <i>Takayasu Arteritis</i> (PTK2B, LILRA3/LILR	Persamaan : - Jenis penyakit - Menggunakan katalog GWAS Perbedaan : - Menggunakan nilai <i>p-value</i> ($5,0 \times 10^{-6}$)

Nama, Peneliti, Tahun	Judul Penelitian	Metode Penelitian	Hasil Penelitian	Perbedaan dan Persamaan Penelitian
			B2, DUSP22, dan KLHL33) serta dua lokus tambahan (FCGR3A dan 21q.22) yang sebelumnya tidak dilaporkan pada populasi non Eropa.	$< p < 5,0 \times 10^{-5}$) - Tidak menggun akan gen <i>missense</i>



DAFTAR PUSTAKA

- Al-mukhtar, A., Ubeid, M. H., Al-mukhtar, N., & Hassan, A. (2025). Clinical Parameters and Association of CCHCR1 Single- Nucleotide Polymorphisms in Psoriasis Arthritis Patients. *Medical Journal of Babylon*, 1(1), 140–146. <https://doi.org/10.4103/mjbl.mjbl>
- Ali, D. A., Ali, N. A., Al-shuhaib, M. B. S., & Aljubouri, T. R. S. (2024). A Novel Intron Variant in the Prolactin Gene Associated with Eggshell Weight and Thickness with Putative Alternative Splicing Patterns in Chickens. *Journal of Genetics*, 103(30), 1–12. <https://doi.org/10.1007/s12041-024-01482-w>
- Aprilita, R., & Topik, M. M. (2024). Manifestasi Klinis dan Penatalaksanaan Vaskulitis. *Jurnal Kedokteran Dan Kesehatan Mahasiswa Malikussaleh*, 3(5), 82–92.
- Ashraf, B., Lawson, D. J., & Lawson, D. J. (2021). Genetic Drift from the Out-of-Africa Bottleneck Leads to Biased Estimation of Genetic Architecture and Selection. *European Journal of Human Genetics*, 29, 1549–1556. <https://doi.org/10.1038/s41431-021-00873-2>
- Astuti, F., Capritasari, R., Iskardyani, D., Alifiar, I., & Irham, L. M. (2023). Identifikasi Variasi Dan Ekspresi Gen Pada Stroke Iskemik Dengan Pendekatan Bioinformatika. *Jurnal Kesehatan Bakti Tunas Husada: Jurnal Ilmu-Ilmu Keperawatan, Analis Kesehatan Dan Farmasi*, 23(1). <https://doi.org/10.36465/jkbth.v23i1.1302>
- Bellil, H., Ghieh, F., Hermel, E., Mandon-pepin, B., & Vialard, F. (2021). Human Testis-Expressed (TEX) Genes : a Review Focused on Spermatogenesis and Male Fertility. *Basic and Clinical Andrology*, 31(9), 1–15.
- Bhandari, S., Butt, S. R. R., Ishfaq, A., Attaallah, M. H., Ekhtator, C., Halappa Nagaraj, R., Mulmi, A., Kamran, M., Karski, A., Vargas, K. I., Lazarevic, S., Zaman, M. U., Lakshmipriya Vetrivendan, G., Shahzed, S. M. I., Das, A., Yadav, V., Bellegarde, S. B., & Ullah, A. (2023). Pathophysiology, Diagnosis, and Management of Takayasu Arteritis: A Review of Current Advances. *Cureus*, 15(7). <https://doi.org/10.7759/cureus.42667>

- Botha, E. (2023). An Overview of Takayasu Arteritis at an Academic Hospital in Central South Africa. In *Faculty of Health Sciences, University of the Free State*.
- Capritasari, R., Irham, L. M., Azzahra, F., & Nugraha, D. (2023). Identifikasi Varian Genetik terkait Kejadian Infark Miokard Melalui Pendekatan Bioinformatik Identification Of Genetic Variants Associated With Myocardial Infarction Through Bioinformatics Approach. *Jurnal Kesehatan Bakti Tunas Husada : Jurnal Ilmu Ilmu Keperawatan, Analisis Kesehatan Dan Farmasi*, 23(1), 29–37.
- Casares-mar, D. (2025). Functional and Practical Insights Into the Genetic Basis of Takayasu Arteritis. *ACR Open Rheumatology*, 7(1), 1–9. <https://doi.org/10.1002/acr2.11766>
- Casares-Marfil, D., & Sawalha, A. H. (2025). Functional and Practical Insights Into the Genetic Basis of Takayasu Arteritis. *ACR Open Rheumatology*, 7(1), 1–9. <https://doi.org/10.1002/acr2.11766>
- Cerezo, M. (2025). The NHGRI-EBI GWAS Catalog: Standards for Reusability, Sustainability and Diversity. *Nucleic Acids Research*, 53(D1), D998–D1005. <https://doi.org/10.1093/nar/gkae1070>
- Chair, M., Setyohadi, B., Anggoro, R. S., & Ariane, A. (2018). Takayasu Arteritis : Diagnostic Approach. *Indonesian Journal of Rheumatology*, 10(2), 105–109. <https://doi.org/10.37275/ijr.v10i2.102>
- Chandhu, A. S., & Danda, D. (2023). Current Diagnosis and Management of Takayasu Arteritis. *International Heart Journal*, 64(4), 519–534. <https://doi.org/10.1536/ihj.23-195>
- Chen, C., Lin, H., Pan, C., & Chen, F. (2016). The Genomic Features that Affect the Lengths of 5' Untranslated Regions in Multicellular Eukaryotes. *BMC Bioinformatics*, 12(Suppl 9), 1–8.
- Comarmond, C., Biard, L., Lambert, M., Mekinian, A., Ferfar, Y., Kahn, J. E., Benhamou, Y., Chiche, L., Koskas, F., Cluzel, P., Hachulla, E., Messas, E., Resche-Rigon, M., Cacoub, P., Mirault, T., & Saadoun, D. (2017). Long-term

- outcomes and prognostic factors of complications in Takayasu arteritis: A multicenter study of 318 patients. *Circulation*, 136(12), 1114–1122. <https://doi.org/10.1161/CIRCULATIONAHA.116.027094>
- Dammacco, F., Cirulli, A., Simeone, A., Leone, P., Pulli, R., Angiletta, D., Rubini, G., Di Palo, A., Vacca, A., & Dammacco, R. (2021). Takayasu arteritis: a cohort of Italian patients and recent pathogenetic and therapeutic advances. *Clinical and Experimental Medicine*, 21(1), 49–62. <https://doi.org/10.1007/s10238-020-00668-7>
- Eisenberger, T., Neuhaus, C., Khan, A. O., Decker, C., Preising, M. N., Friedburg, C., Bieg, A., Gliem, M., Issa, P. C., Holz, F. G., & Baig, S. M. (2017). Increasing the Yield in Targeted Next-Generation Sequencing by Implicating CNV Analysis , Non-Coding Exons and the Overall Variant Load : The Example of Retinal Dystrophies. *PLOS ONE*, 8(11), 1–18. <https://doi.org/10.1371/journal.pone.0078496>
- Fadly, A., Rifaannudin, M., Badrun, M., & Maghfiroh, N. (2023). Nafs Wahidah dalam Al-Qur'an Al-Karim Menurut Zaghulul Raghil Muhammad An-Najjar. *ZAD Al-Mufassirin*, 5(1), 60–77.
- Febrina, A. (2015). Takayasu's Arteritis. *CDK-233*, 42(10), 741–743.
- Fernandez, X.M., E. B. (2017). Ensembl Genome Browser. *M.R. Speicher et Al. (Eds.), Vogel and Motulsky's Human Genetics: Problems and Approaches, January 2010*, 923–939. <https://doi.org/10.1007/978-3-540-37654-5>
- Fierro-, A., Roca-umbert, A., Id, J. G., Vogel-gonza, M., Ill-raga, G., Id, F. C., & Gutie, E. (2023). Human Genetic Adaptation Related to Cellular Zinc Homeostasis. *PLOS Genetics*, 10(1371), 1–33. <https://doi.org/10.1371/journal.pgen.1010950>
- Fitri, D., Irham, L. M., Sulistyani, N., Ma'ruf, M., Puspitaningrum, A. N., Adikusuma, W., Mazaya, M., & Chong, R. (2024). Integration of genomics database and bioinformatics to identify genome-wide variants for myasthenia gravis across multiple continents. *Brain Behavior and Immunity Integrative*, 5(August 2023), 100041. <https://doi.org/10.1016/j.bbii.2023.100041>

- Flynn, E. D., Tsu, A. L., Kasela, S., Kim-hellmuth, S., Aguet, F., Ardlie, K. G., & Bussemaker, H. J. (2022). Transcription Factor Regulation of eQTL Activity across Individuals and Tissues. *PLOS Genetics*, 18(1), 1–25. <https://doi.org/10.1371/journal.pgen.1009719>
- Gloor, A. D., Chollet, L., Christ, L. A., Cullmann, J. L., Bonel, H. M., & Villiger, P. M. (2021). Takayasu arteritis: Prevalence and clinical presentation in Switzerland. *PLoS ONE*, 16(6 June). <https://doi.org/10.1371/journal.pone.0250025>
- GTEx Portal. (2026). *How Should eQTL Effect Sizes be Interpreted?* GTEx Portal. <https://gtexportal.org>
- Hara, A., Lu, E., Johnstone, L., Wei, M., Hallmark, B., Watkins, J. C., Zhang, H. H., Yao, G., & Chilton, F. H. (2024). Identification of an Allele-Specific Transcription Factor Binding Interaction that May Regulate PLA2G2A Gene Expression. *Bioinformatics and Biology Insights*, 18, 1–10. <https://doi.org/10.1177/11779322241261427>
- Hernández-torres, F., Rastrojo, A., & Aguado, B. (2017). Intron Retention and Transcript Chimerism Conserved across Mammals : Ly6g5b and Csnk2b-Ly6g5b as Examples. *BMC Genomics*, 14(199), 1–12.
- Huang, R., He, Y., Sun, B., & Liu, B. (2018). Bioinformatic analysis identifies three potentially key differentially expressed genes in peripheral blood mononuclear cells of patients with takayasu's arteritis. *Cell Journal*, 19(4), 647–653. <https://doi.org/10.22074/cellj.2018.4991>
- Jagtap, S., Mishra, P., Rathore, U., Thakare, D. R., Singh, K., Dixit, J., Qamar, T., Behera, M. R., Jain, N., Ora, M., Bhadauria, D. S., Gambhir, S., Kumar, S., Agarwal, V., & Misra, D. P. (2024). Increased mortality rate in Takayasu arteritis is largely driven by cardiovascular disease: a cohort study. *Rheumatology*, 63(12), 3337–3345. <https://doi.org/10.1093/rheumatology/kead584>
- Jannot, A.-S., Ehret, G., & Perneger, T. (2017). $P < 5 \times 10^{-8}$ has emerged as a standard of statistical significance for genome-wide association studies.

- Journal of Clinical Epidemiology*, 68(4), 460–465.
<https://doi.org/https://doi.org/10.1016/j.jclinepi.2015.01.001>
- Joseph, G., Goel, R., Thomson, V. S., Joseph, E., & Danda, D. (2023). Takayasu Arteritis: JACC Focus Seminar 3/4. *Journal of the American College of Cardiology*, 81(2), 172–186. <https://doi.org/10.1016/j.jacc.2022.09.051>
- Kartikasari, A. L. N., Wibowo, A. D. K., Prasetya, H. B., Malihi, L., Sulistyani, N., Irham, L. M., Adikusuma, W., Septama, A. W., Khair, R. El, & Satria, R. D. (2023). Identifikasi Variasi Gendan Ekspresi Gen yang Berhubungan dengan Anemia Aplastik Menggunakan Pendekatan Genomik dan Bioinformatika. *Lambung Farmasi, Jurnal Ilmu Kefarmasian*, 4(2), 300–306.
- Kato, Y., Terashima, M., Ohigashi, H., Tezuka, D., Ashikaga, T., Hirao, K., & Isobe, M. (2015). Vessel wall inflammation of Takayasu arteritis detected by Contrast-enhanced Magnetic resonance imaging: Association with disease distribution and activity. *PLoS ONE*, 10(12). <https://doi.org/10.1371/journal.pone.0145855>
- Katsicas, R. &. (2018). Takayasu Arteritis. *Frontiers in Pediatrics*, 6(265), 1–17. <https://doi.org/10.3389/fped.2018.00265>
- Kim-hellmuth, S., Liang, Y., Oliva, M., Parsana, P., Muñoz-aguirre, M., Park, Y., Saha, A., Segrè, A. V., & Strober, B. J. (2020). The GTEx Consortium Atlas of Genetic Regulatory Effects across Human Tissues. *Science*, 369(6509), 1318–1330. <https://doi.org/10.1126/science.aaz1776>.Author
- Kurniawati, S., Hartati, N. S., Hartati, H., & Sudarmonowati, E. (2020). The Polymorphic Gene of Single Nucleotide Polymorphism (SNP) of Phytoene Synthase (PSY) to Characterize Carotenoids Yellow Root Cassava. *Jurnal ILMU DASAR*, 21(1), 19. <https://doi.org/10.19184/jid.v21i1.9197>
- Laurent, C., Prieto-González, S., Belnou, P., Carrat, F., Fain, O., Dellal, A., Cid, M. C., Hernández-Rodríguez, J., & Mekinian, A. (2021). Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. *Scientific Reports*, 11(1), 1–6. <https://doi.org/10.1038/s41598-021-93416-0>

- Li, X., Yang, P., Dong, B., Shao, N., Cheng, J., & Yuan, Z. (2025). Microglial PRRC2A Regulates Microglia-Neuron Interaction in Cerebellum and Motor Functions in Mice. *IScience*, 28(113949), 11–17. <https://doi.org/10.1016/j.isci.2025.113949>
- Liao, H., Zhang, N., Pan, L., Du, J., Liu, J., & Zheng, Y. (2023). Predictors for Pulmonary Artery Involvement in Takayasu Arteritis and its Cluster Analysis. *Arthritis Research & Therapy*, 25(9), 1–13. <https://doi.org/10.1186/s13075-022-02987-4>
- Liu, L., Chen, J., Li, J., Yang, Y., Zeng, X., & Tian, X. (2022). Whole Exome Sequencing Revealed Variants That Predict Pulmonary Artery Involvement in Patients with Takayasu Arteritis. *Journal of Inflammation Research*, 15, 4817–4831. <https://doi.org/10.2147/JIR.S377402>
- Lusida, M., Kurniawan, M. Z., & Nugroho, J. (2020). Takayasu arteritis in a rural hospital in Indonesia. *BMJ Case Reports*, 13(1), 3–6. <https://doi.org/10.1136/bcr-2019-230884>
- Magno, R., & Maia, A. T. (2020). Gwasrapidd: An R package to query, download and wrangle GWAS catalog data. *Bioinformatics*, 36(2), 649–650. <https://doi.org/10.1093/bioinformatics/btz605>
- Mahrus, Lalu Zulkifli, Saprizal Hadisaputra, & Ida Ayu Putu Armyani. (2021). Penggunaan Bioinformatika dalam Pembelajaran Sains Untuk Menyelesaian Kesulitan Belajar Siswa pada Materi Genetika di SMPN 20 Mataram. *Jurnal Pengabdian Magister Pendidikan IPA*, 4(4), 290–295. <https://doi.org/10.29303/jpmppi.v4i4.1128>
- Mamfaluti, T., Zurwida, Febriliant, M. R., & Firdaus, S. (2023). Diagnostik Vaskulitis Primer pada Penyakit Immunologi. *Jurnal Kedokteran Nanggroe Medika*, 6(1), 41–59.
- Mathé, J., Brochu, S., Adam, D., & Brochiero, E. (2024). Sex and Disease Regulate MHC I Expression in Human Lung Epithelial Cells. *Research Article*, 1(1), 1–33.
- Medi Sushanti, N., Wirawan Adikusuma, Anisa Nova Puspitaningrum, Arief

- Rahman Afief, & Lalu Muhammad Irham. (2023). Drug Repurposing Untuk Rheumatoid Arthritis Melalui Pemanfaatan Data Variasi Genetik. *Medical Sains : Jurnal Ilmiah Kefarmasian*, 8(2), 747–754. <https://doi.org/10.37874/ms.v8i2.720>
- Mitchell, J. (2024). Molecular Mechanisms of Gene Regulation : From Promoters to Enhancers. *J Biochem Biotech*, 7(4), 1–2. <https://doi.org/10.35841/aabb-7.4.212>
- Nabilla, P. D., & Irham, L. M. (2024). Profile Mapping of Gene Variations Associated with Breast Cancer and its Vulnerability in The World Populations Using a Genomic Database. *Media Farmasi: Jurnal Ilmu Farmasi*, 19(1), 1–6.
- Naqvi, W., Garg, P., & Srivastava, P. (2025). Transcriptome Derived Artificial Neural Networks Predict PRRC2A as a Potent Biomarker for Epilepsy. *Journal of Genetic Engineering and Biotechnology*, 23(2), 100503. <https://doi.org/https://doi.org/10.1016/j.jgeb.2025.100503>
- Natasya, R. (2025). *Identifikasi Variasi Gen pada Penyakit Tourette Syndrome dengan Menggunakan Database Genomik dan Bioinformatika*, Skripsi,. Program Studi S1 Farmasi Klinis & Komunitas, Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin.
- National Library of Medicine. (2017). *CCHCR1 Coiled-Coil Alpha-Helical Rod Protein 1*. www.ncbi.nlm.nih.gov
- National Library of Medicine. (2026a). *LY6G5B Lymphocyte Antigen 6 Family Member G5B*. www.ncbi.nlm.nih.gov
- National Library of Medicine. (2026b). *LY6G6F Lymphocyte Antigen 6 Family Member G6F*. www.ncbi.nlm.nih.gov
- Ohigashi, H., Haraguchi, G., Konishi, M., Tezuka, D., Kamiishi, T., Ishihara, T., & Isobe, M. (2018). Improved prognosis of Takayasu arteritis over the past decade - comprehensive analysis of 106 patients -. *Circulation Journal*, 76(4), 1004–1011. <https://doi.org/10.1253/circj.CJ-11-1108>
- Ortiz-Fernández, L. (2021a). Identification of Susceptibility Loci for Takayasu

- Arteritis Through a Large Multi-Ancestral Genome-Wide Association Study. *American Journal of Human Genetics*, 108(1), 84–99. <https://doi.org/10.1016/j.ajhg.2020.11.014>
- Ortiz-Fernández, L. (2021b). Identification of Susceptibility Loci for Takayasu Arteritis Through a Large Multi-Ancestral Genome-Wide Association Study. *American Journal of Human Genetics*, 108(1), 84–99. <https://doi.org/10.1016/j.ajhg.2020.11.014>
- Oura, K., Yamaguchi Oura, M., Itabashi, R., & Maeda, T. (2021). Vascular imaging techniques to diagnose and monitor patients with takayasu arteritis: A review of the literature. *Diagnostics*, 11(11). <https://doi.org/10.3390/diagnostics11111993>
- Pangemanan, D. H. C., & Marunduh, S. R. (2016). Profil Tumor Necrosis Factor (TNF- α) Berdasarkan Indeks Massa Tubuh (IMT). *Jurnal E-Biomedik (EBm)*, 3(2), 640–643.
- Petrosino, M., Novak, L., Pasquo, A., Chiaraluce, R., Turina, P., Capriotti, E., & Consalvi, V. (2021). Analysis and Interpretation of the Impact of Missense Variants in Cancer. *International Journal of Molecular Sciences*, 22(5416), 1–22.
- Pilalis, E., Zisis, D., Andrinopoulou, C., Karamanidou, T., Antonara, M., Stavropoulos, T. G., & Chatziioannou, A. (2025). Genome-Wide Functional Annotation of Variants: A Systematic Review of State of the Art Tools, Techniques and Resources. *Frontiers in Pharmacology*, 1474026(16), 1–17. <https://doi.org/10.3389/fphar.2025.1474026>
- Rajlawot, K., Thapa, S., Sitaula, A., & Neupane, N. P. (2022). Spectrum of imaging findings in Takayasu arteritis—A case report. *Radiology Case Reports*, 17(10), 3470–3474. <https://doi.org/10.1016/j.radcr.2022.06.092>
- Renauer, P & Sawalha, A, H. (2017). The Genetics of Takayasu Arteritis. *Presse Med*, 46, 1–13. <https://doi.org/10.1016/j.lpm.2016.11.031>
- Rezadhini, M., Irham, L. M., Puspitaningrum, A. N., Afief, A. R., Adikusuma, W., & Perwitasari, D. A. (2023). Utilizing A Genomic Database for Identifying

- Genomic Variation for SARS-Cov-2 Receptors. *Medical Sains : Jurnal Ilmiah Kefarmasian*, 8(2), 667–678. <https://doi.org/10.37874/ms.v8i2.790>
- Rojano, E., Seoane, P., Ranea, J. A. G., & Perkins, J. R. (2019). Regulatory Variants : From Detection to Predicting Impact. *Briefings in Bioinformatics*, 20(5), 1639–1654. <https://doi.org/10.1093/bib/bby039>
- Romo, L., Findlay, S. D., Burge, C. B., Romo, L., Findlay, S. D., & Burge, C. B. (2024). Regulatory Features Aid Interpretation of 3'UTR Variants. *The American Journal of Human Genetics*, 111, 350–363. <https://doi.org/10.1016/j.ajhg.2023.12.017>
- Rotimi, C. N., Bentley, A. R., Doumatey, A. P., Chen, G., Shriner, D., & Adeyemo, A. (2017). The Genomic Landscape of African Populations in Health and Disease. *Human Molecular Genetics*, 26(R2), 225–236. <https://doi.org/10.1093/hmg/ddx253>
- Rutter, M., Bowley, J., Lanyon, P. C., Grainge, M. J., & Pearce, F. A. (2021). A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. *Rheumatology*, 60(11), 4982–4990. <https://doi.org/10.1093/rheumatology/keab406>
- Saadoun, D. (2021). French Recommendations for The Management of Takayasu's Arteritis. *Orphanet Journal of Rare Diseases*, 16(Suppl 3), 1–23. <https://doi.org/10.1186/s13023-021-01922-1>
- Sakurai, N., Ikawa, M., Fujihara, Y., & Kobayashi, K. (2024a). CRISPR / Cas9-Mediated Disruption of Lipocalins, Ly6g5b, and Ly6g5c Causes Male Subfertility in Mice. *Andrology*, 12(June 2022), 981–990. <https://doi.org/10.1111/andr.13350>
- Sakurai, N., Ikawa, M., Fujihara, Y., & Kobayashi, K. (2024b). CRISPR / Cas9-Mediated Disruption of Lipocalins , Ly6g5b , and Ly6g5c Causes Male Subfertility in Mice. *Androl*, 12(November 2022), 981–990. <https://doi.org/10.1111/andr.13350>
- Sanchez-alvarez, C., Crowson, C. S., Ph, D., & Koster, M. J. (2022). The epidemiology of Takayasu Arteritis, a population-based study. *J Rheumatol*,

- 48(6), 1–4. <https://doi.org/10.3899/jrheum.201463>. The
- Sardi, A. (2022). Bioinformatics: Challenges in Integrating Biological Information. *Jurnal Biologi Tropis*, 22(4), 1297–1301. <https://doi.org/10.29303/jbt.v22i4.4346>
- Satriyanto, M. D. (2020). Penatalaksanaan Anestesi pada Pasien yang Menjalani Seksio Sesar dengan Penyakit Takayasu Arteritis. *Collaborative Medical Journal (CMJ)*, 3(2), 91–98.
- Schott, G., & Garcia-blanco, M. A. (2021). MHC Class III RNA Binding Proteins and Immunity. *RNA Biology*, 18(5), 640–646. <https://doi.org/10.1080/15476286.2020.1860388>
- Sezgin, E., & Kaplan, E. (2022). Diverse Selection Pressures Shaping the Genetic Architecture of Behçet Disease Susceptibility. *Frontiers in Genetics*, 1(September), 1–15. <https://doi.org/10.3389/fgene.2022.983646>
- Sharma, P., Kumar, P., & Sharma, R. (2017). The Major Histocompatibility Complex: A Review. *Asian Journal of Pharmaceutical and Clinical Research*, 10(2), 33–36.
- Sianu, R. S., Jannah, M., & Mauri, A. (2025). Identifikasi Kandidat Target Obat Ulcerative Colitis (UC) Menggunakan Pendekatan Bioinformatika Menuju Precision Medicine. *Herbal Medicine Journal*, 8((2)), 10–28.
- Sollis, E. (2023). The NHGRI-EBI GWAS Catalog: Knowledgebase and Deposition Resource. *Nucleic Acids Research*, 51(1 D), D977–D985. <https://doi.org/10.1093/nar/gkac1010>
- Souza Pedreira, A. L., Leite de Castro Flores, M., & Barreto Santiago, M. (2024). Interleukin 6 Levels and Disease Activity in Takayasu Arteritis: A Systematic Review With Meta-analysis. *Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases*, 30(2), 58–64. <https://doi.org/10.1097/RHU.0000000000002053>
- Stamatis, P. (2020). Giant Cell Arteritis versus Takayasu Arteritis: An Update. *Mediterr J Rheumatol*, 31(2), 174–182.
- Stanfill, A. G., & Cao, X. (2021). Enhancing Research Through the Use of the

- Genotype-Tissue Expression (GTEx) Database. *Biological Research for Nursing*, 23(3), 533–540. <https://doi.org/10.1177/1099800421994186>
- Suryono, S., Wulandari, P., Ariyanti, D., Maulana, A. S., Sembodo, R. H., Junior, N. W., & Saputra, A. D. (2022). Takayasu arteritis with congestive heart failure in 26-year-old male: a case report. *Egyptian Heart Journal*, 74(1), 4–9. <https://doi.org/10.1186/s43044-022-00279-5>
- Svecla, M., Li-gao, R., Falck, D., & Bonacina, F. (2025). N-glycosylation Signature and its Relevance in Cardiovascular Immunometabolism. *Vascular Pharmacology*, 159(October 2024), 107474. <https://doi.org/10.1016/j.vph.2025.107474>
- Terao, C. (2018). Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. *American Journal of Human Genetics*, 93(2), 289–297. <https://doi.org/10.1016/j.ajhg.2013.05.024>
- Terao, C. (2018). Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. *Proceedings of the National Academy of Sciences of the United States of America*, 115(51), 13045–13050. <https://doi.org/10.1073/pnas.1808850115>
- Vaideeswar, P., & Deshpande, J. R. (2017). Pathology of Takayasu arteritis: A brief review. *Annals of Pediatric Cardiology*, 6(1), 52–58. <https://doi.org/10.4103/0974-2069.107235>
- Venketasubramanian, N. (2016). Diagnosis and management of Takayasu arteritis. *Perspectives in Medicine*, 1–12(1–12), 255–256. <https://doi.org/10.1016/j.permed.2012.02.032>
- Ward, L. D., & Kellis, M. (2016). HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Research*, 44(D1), D877–D881. <https://doi.org/10.1093/nar/gkv1340>
- Wibisono, I. S., & Putri, M. A. (2021). Analisis Ekspresi Gen Menggunakan Medical Imaging untuk Pendeteksi Penyakit. *Jurnal Cakrawala Informasi*,

- 1(2), 42–50. <https://doi.org/10.54066/jci.v1i2.149>
- Wira Pratama Yasa, A. A. G., Lina Kamelia, L. P., & Lestari, M. W. (2022). Arteritis Takayasu. *Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia*, 39(3), 134–139. <https://doi.org/10.52386/neurona.v39i3.328>
- Wurfel. (2022). HLA-H, HLA-J, HLA-L, HLA-V and HLA-Y as Therapeutic and Diagnostic Targets. *Patent Application Publication*, 1(2), 1–57.
- Yadav, M. L., & Mohapatra, B. (2018). Genic Versus Intergenesis Region. *Encyclopedia of Animal Cognition and Behavior*, 1, 1–5.
- Zeng, Z., & Bromberg, Y. (2019). Predicting Functional Effects of Synonymous Variants: A Systematic Review and Perspectives. *Frontiers in Genetics*, 10(October), 1–15. <https://doi.org/10.3389/fgene.2019.00914>
- Zhang, J., Chen, M.-J., Zhao, G.-X., Li, H.-F., Wu, L., Xu, Y.-F., Liao, Y., Yuan, Z., & Wu, Z.-Y. (2021). Common Genetic Variants in PRRC2A are Associated with Both Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Han Chinese Population. *Journal of Neurology*, 268(2), 506–515. <https://doi.org/10.1007/s00415-020-10184-z>
- Zhang, J., Wu, Q., Zhang, S., Cho, S., Sze, W., & Li, C. (2025). CCHCR1 Links P - Body Proteins to the Centrosome and is Required for Ciliogenesis Through Interacting with OFD1 and PCM1. *Cellular & Molecular Biology Letters*, 30(103), 1–25.
- Zhang, J., & Zhao, H. (2023). eQTL Studies: from Bulk Tissues to Single Cells. *Journal of Genetics and Genomics*, 50(12), 925–933. <https://doi.org/10.1016/j.jgg.2023.05.003>
- Zolotareva, O. (2019). Review Article A Survey of Gene Prioritization Tools for Mendelian and Complex Human Diseases. *Journal of Integrative Bioinformatics*, 10(1), 1–20. <https://doi.org/10.1515/jib-2018-0069>

LAMPIRAN



Lampiran 1. Lembar Bimbingan Proposal

	UNIVERSITAS MUHAMMADIYAH GOMBONG	Nomor	: PDN-SKP/12/005
		Revisi ke	: 02
		Tgl. Terbit	: 18 Agustus 2020
		Halaman	

LEMBAR BIMBINGAN PROPOSAL SKRIPSI

Nama mahasiswa : Nabila Aulfa Rahma
 NIM : 202205046
 Nama Pembimbing : apt. Puji Kurniati, M. Farm.

Tanggal Bimbingan	Topik/Materi Bimbingan	Paraf Mahasiswa	Paraf Pembimbing
26/9/2025	Bimbingan judul		
29/9/2025	Bimbingan judul, penyesuaian judul		
13/10/2025	Bimbingan Bab I		
24/10/2025	ACC Bab I		
22/11/2025	Bimbingan bab II & III, ACC Bab II & III, Bimbingan PPT KEMPRO		

Gombong, ¹² Bulan ¹² Tahun ²⁰²⁵

Mengetahui,

Koordinator Skripsi


 apt. Wahyu Rahmatulloh, M.Farm
 NIDN : 0617039602

Ka. Prodi ST Farmasi


 Dr. apt. Naclaz Zukhruf WK, M.Pharm.Sci
 NIDN : 0618109202

Lampiran 2. Lembar Bimbingan Hasil



UNIVERSITAS MUHAMMADIYAH GOMBONG
FAKULTAS ILMU KESEHATAN
PROGRAM STUDI FARMASI PROGRAM SARJANA
 Jl. Yos Sudarso No. 461 Gombong, Kebumen 54412 Telp./Fax. (0287) 472433, 473750
 Website: www.unumgo.ac.id E-mail: s1farmasi@unumgo.ac.id

LEMBAR BIMBINGAN HASIL SKRIPSI

Nama Mahasiswa : NABILA AULIA RAHMA
 NIM : 202205046
 Nama Pembimbing : apt. Dwiki Fitri, M.Farm

Tanggal	Topik/Materi Bimbingan	Paraf Mahasiswa	Paraf Pembimbing
09 April 2026	Bimbingan bab 4 (hasil)		
12 April 2026	Revisi bab 4, bimbingan bab 5		
20 April 2026	ACC Bab 4, revisi Bab 5		
08 Mei 2026	revisi Bab 5 (pembahasan)		
09 Mei 2026	revisi Bab 5, Bimbingan abstrak		
12 Mei 2026	ACC Bab 5, revisi abstrak		
13 Mei 2026	ACC abstrak.		

Gombong, 12 Bulan Mei Tahun 2026

Mengetahui,
 Koordinator Skripsi

apt. Wahyu Rahmatulloh, M.Farm

Ka. Prodi S1 Farmasi

apt. Tri Cahyani Widiastuti, M.Sc



DOKUMEN TERVERIFIKASI SISTEM SIMPUS

No : LB-H/FAR/2026/5046-FW6RM

Nama : NABILA AULIA RAHMA

NIM : 202205046

Tgl : 01 April 2026

Scen QR untuk verifikasi keaslian dokumen.

Tidak sah tanpa tanda tangan bawahi koordinator skripsi dan ka prodi s1 farmasi



Dokumen ini dicetak melalui
 Aplikasi SIMPLUS Farmasi UM Gombong

Lampiran 3. Lembar Bimbingan Abstrak



UNIVERSITAS MUHAMMADIYAH GOMBONG
FAKULTAS ILMU KESEHATAN
PROGRAM STUDI FARMASI PROGRAM SARJANA
 Jl. Yos Sudarso No. 461 Gombong, Kebumen 54412 Telp/Fax. (0287) 472433, 473750
 Website: www.unimago.ac.id E-mail: si.farmasi@unimago.ac.id

LEMBAR REVISI ABSTRAK SKRIPSI

Nama Mahasiswa	: NABILA AULIA RAHMA
NIM	: 202205046
Judul Skripsi	: STUDI BIOINFORMATIKA VARIASI DAN EKSPRESI GEN YANG
Tanggal Ujian	: Selasa, 26/05/2026 07.30-09.00
Tempat Ujian	: Ruang G302
Batas Akhir Revisi	: 26 Juni 2026

NO	REVISI	FARAF PEMBIMBING
1.	Revisi abstrak bahasa Inggris	
2.	add abstrak.	
3.		
4.		
5.		
6.		
7.		
8.		
9.		
10.		

Gombong, 19 bulan Juni tahun 2026

Koordinator Skripsi,

apt. Wahyu Rahmatulloh, M.Farm

Pembimbing Abstrak,

Khamim Mustopo, M.pd.



DOKUMEN TERVERIFIKASI SISTEM SIMPUS

No : LRA/FAR/2025/5046-YJDBZX
 Nama : NABILA AULIA RAHMA
 NIM : 202205046
 Tgl : 15 Juni 2026

Scan QR untuk verifikasi keaslian dokumen.

Tidak sah tanpa tanda tangan basah koordinator skripsi dan pembimbing abstrak



Dokumen ini dicetak melalui
 Aplikasi SIMPUS Farmasi UIM Gombong

Lampiran 4. Surat Pernyataan Tidak Melakukan Etik Penelitian



UNIVERSITAS MUHAMMADIYAH GOMBONG
FAKULTAS ILMU KESEHATAN
PROGRAM STUDI FARMASI PROGRAM SARJANA
Jl. Yos Sudarso No. 461 Gombong, Kebumen 54412 Telp./Fax. (0287) 472433, 473750
Website: www.unimugo.ac.id E-mail: s1farmasi@unimugo.ac.id

SURAT PERNYATAAN TIDAK MELAKUKAN ETIK PENELITIAN

Nomor : ETK/FAR/2026/50460670
Tanggal : Gombong, 8 Mei 2026

Assalamu'alaikum wr wb

Saya yang bertanda tangan dibawah ini:

Nama : NABILA AULIA RAHMA
NIM : 202205046
Prodi : Farmasi Program Sarjana
Judul skripsi : STUDI BIOINFORMATIKA VARIASI DAN EKSPRESI GEN YANG
BERHUBUNGAN DENGAN TAKAYASU ARTERITIS (TA)

Menerangkan bahwa penelitian yang saya lakukan tidak bersinggungan dengan subyek yang berkaitan dengan manusia ataupun hewan. Demikian surat pernyataan ini saya buat dengan sebenar-benarnya dan untuk dipergunakan sebagai salah satu persyaratan ujian hasil penelitian (skripsi). Terimakasih.

Wassalamu'alaikum wr wb

Peneliti,

NABILA AULIA RAHMA
NIM. 202205046

Mengetahui,

Dosen Pembimbing Utama

apt. Dwiki Fitri, M.Farm
NUPTK. 443577678230072



DOKUMEN TERVERIFIKASI SISTEM SIMPUS

No : ETK/FAR/2026/50460670
Nama : NABILA AULIA RAHMA
NIM : 202205046
Tgl : 8 Mei 2026

Scan QR untuk verifikasi keaslian

Tidak sah tanpa tanda tangan basah peneliti dan dosen pembimbing



Dokumen ini dicetak melalui
Aplikasi SIMBUS Farmasi UM Gombong

Lampiran 5. Surat Pernyataan Bebas Plagiarisme



SURAT PERNYATAAN CEK SIMILARITY/PLAGIASI

Yang bertanda tangan di bawah ini Pustakawan Universitas Muhammadiyah Gombong. Menyatakan bahwa karya tulis di bawah ini **sudah lolos** uji cek similarity/plagiasi:

Judul : Studi Bioinformatika Variasi dan Ekspresi Gen yang Berhubungan dengan Takayasu Arteritis
Nama : Nabila Aulia Rahma
NIM : 202205046
Program Studi : Farmasi Program Sarjana
Hasil Cek : 8 %

Gombong, 11 Mei 2026

Mengetahui,

Pustakawan Universitas Muhammadiyah Gombong


Drs. Sundani Yati

Lampiran 6. Hasil Analisi SNP yang ditemukan pada Basis Data Katalog GWAS sebanyak 166

No	SNPs	<i>p-value</i>	No	SNPs	<i>p-value</i>
1	rs74712413	1 x 10 ⁻⁵	34	rs2852306	5 x 10 ⁻⁶
2	rs74712413	1 x 10 ⁻⁵	35	rs9615754	4 x 10 ⁻⁶
3	rs13260543	9 x 10 ⁻⁶	36	rs9615754	4 x 10 ⁻⁶
4	rs12419742	9 x 10 ⁻⁶	37	rs410852	4 x 10 ⁻⁶
5	rs3847061	9 x 10 ⁻⁶	38	rs7956657	4 x 10 ⁻⁶
6	rs1250566	9 x 10 ⁻⁶	39	chr6:33036435	4 x 10 ⁻⁶
7	rs11675428	8 x 10 ⁻⁶	40	rs1868971	3 x 10 ⁻⁶
8	rs12511310	8 x 10 ⁻⁶	41	rs10816540	3 x 10 ⁻⁶
9	rs9380294	7 x 10 ⁻⁶	42	rs375244	3 x 10 ⁻⁶
10	rs5875188	7 x 10 ⁻⁶	43	rs12596533	3 x 10 ⁻⁶
11	rs2660739	7 x 10 ⁻⁶	44	rs56167332	2 x 10 ⁻⁶
12	rs76139923	7 x 10 ⁻⁶	45	rs10470752	2 x 10 ⁻⁶
13	rs1877209	7 x 10 ⁻⁶	46	rs3812560	2 x 10 ⁻⁶
14	rs76139923	7 x 10 ⁻⁶	47	rs1113601	2 x 10 ⁻⁶
15	rs115155040	6 x 10 ⁻⁶	48	rs2322599	2 x 10 ⁻⁶
16	rs113569359	6 x 10 ⁻⁶	49	rs8111	1 x 10 ⁻⁶
17	rs2242944	6 x 10 ⁻⁶	50	rs4463283	1 x 10 ⁻⁶
18	rs115155040	6 x 10 ⁻⁶	51	rs34629529	1 x 10 ⁻⁶
19	rs10144053	6 x 10 ⁻⁶	52	rs34629529	1 x 10 ⁻⁶
20	rs7005183	6 x 10 ⁻⁶	53	rs7743661	1 x 10 ⁻⁶
21	rs12571685	6 x 10 ⁻⁶	54	rs9380141	1 x 10 ⁻⁶
22	rs136301	6 x 10 ⁻⁶	55	rs7843437	1 x 10 ⁻⁶
23	rs136301	6 x 10 ⁻⁶	56	rs12608210	1 x 10 ⁻⁶
24	rs7956657	6 x 10 ⁻⁶	57	rs12321966	1 x 10 ⁻⁶
25	rs3817971	5 x 10 ⁻⁶	58	rs4713281	1 x 10 ⁻⁶
26	rs4624865	5 x 10 ⁻⁶	59	rs6560480	9 x 10 ⁻⁷
27	rs9917659	5 x 10 ⁻⁶	60	rs1051957	9 x 10 ⁻⁷
28	rs1462717	5 x 10 ⁻⁶	61	rs2836883	8 x 10 ⁻⁷
29	rs176237	5 x 10 ⁻⁶	62	rs41267090	8 x 10 ⁻⁷
30	rs4981676	5 x 10 ⁻⁶	63	rs1376741	7 x 10 ⁻⁷
31	rs28381348	5 x 10 ⁻⁶	64	rs35409540	7 x 10 ⁻⁷
32	rs6904014	5 x 10 ⁻⁶	65	rs3869115	6 x 10 ⁻⁷
33	rs12492780	5 x 10 ⁻⁶	66	rs142314071	6 x 10 ⁻⁷

No	SNPs	<i>p-value</i>	No	SNPs	<i>p-value</i>
67	rs142314071	6 x 10 ⁻⁷	102	rs2069837	7 x 10 ⁻⁹
68	rs77422524	5 x 10 ⁻⁷	103	rs113452171	4 x 10 ⁻⁹
69	chr6:26264671	5 x 10 ⁻⁷	104	rs58693904	4 x 10 ⁻⁹
70	rs1376741	4 x 10 ⁻⁷	105	rs17133698	3 x 10 ⁻⁹
71	chr21:40462378:D	4 x 10 ⁻⁷	106	rs4379175	3 x 10 ⁻⁹
72	rs10921544	3 x 10 ⁻⁷	107	rs76457959	3 x 10 ⁻⁹
73	rs2457837	3 x 10 ⁻⁷	108	rs28749167	2 x 10 ⁻⁹
74	rs7603494	2 x 10 ⁻⁷	109	rs12111032	1 x 10 ⁻⁹
75	rs1429365	2 x 10 ⁻⁷	110	rs28834970	1 x 10 ⁻⁹
76	rs12047961	2 x 10 ⁻⁷	111	rs1116221	1 x 10 ⁻⁹
77	rs9271539	2 x 10 ⁻⁷	112	chr6:31570670	1 x 10 ⁻⁹
78	rs2069837	2 x 10 ⁻⁷	113	rs9267547	5 x 10 ⁻¹⁰
79	rs2736173	2 x 10 ⁻⁷	114	rs4817988	3 x 10 ⁻¹⁰
80	rs9540128	1 x 10 ⁻⁷	115	rs707936	2 x 10 ⁻¹⁰
81	rs7911604	1 x 10 ⁻⁷	116	rs73426382	2 x 10 ⁻¹⁰
82	rs1611209	1 x 10 ⁻⁷	117	rs1383258	2 x 10 ⁻¹⁰
83	HLA-DQB1*0502	1 x 10 ⁻⁷	118	rs4410768	2 x 10 ⁻¹⁰
84	rs28399987	8 x 10 ⁻⁸	119	rs12526858	2 x 10 ⁻¹⁰
85	rs1610644	8 x 10 ⁻⁸	120	rs12110437	2 x 10 ⁻¹⁰
86	rs9273902	7 x 10 ⁻⁸	121	HLAB*5201	2 x 10 ⁻¹⁰
87	rs7038415	5 x 10 ⁻⁸	122	rs4817984	1 x 10 ⁻¹⁰
88	rs34109750	5 x 10 ⁻⁸	123	rs11229	8 x 10 ⁻¹¹
89	rs28752871	5 x 10 ⁻⁸	124	rs707915	6 x 10 ⁻¹¹
90	rs11666543	4 x 10 ⁻⁸	125	rs3130628	5 x 10 ⁻¹¹
91	HLA-DQB1*0502	4 x 10 ⁻⁸	126	rs3130626	5 x 10 ⁻¹¹
92	rs103294	3 x 10 ⁻⁸	127	rs1062070	5 x 10 ⁻¹¹
93	rs4817984	3 x 10 ⁻⁸	128	rs3130349	5 x 10 ⁻¹¹
94	rs9540128	2 x 10 ⁻⁸	129	rs3130070	4 x 10 ⁻¹¹
95	rs12515766	2 x 10 ⁻⁸	130	rs2736157	4 x 10 ⁻¹¹
96	rs6959179	2 x 10 ⁻⁸	131	rs10885	4 x 10 ⁻¹¹
97	rs9266745	2 x 10 ⁻⁸	132	rs2517985	3 x 10 ⁻¹¹
98	rs12980600	2 x 10 ⁻⁸	133	rs9267535	3 x 10 ⁻¹¹
99	rs1264697	1 x 10 ⁻⁸	134	rs3134940	3 x 10 ⁻¹¹
100	rs2523721	8 x 10 ⁻⁹	135	rs1265078	3 x 10 ⁻¹¹
101	rs1713450	7 x 10 ⁻⁹	136	rs3130627	3 x 10 ⁻¹¹

No	SNPs	<i>p-value</i>	No	SNPs	<i>p-value</i>
137	rs1576	3 x 10 ⁻¹¹	152	rs12524487	6 x 10 ⁻¹⁶
138	rs9267532	3 x 10 ⁻¹¹	153	rs45479291	2 x 10 ⁻¹⁶
139	rs62392216	3 x 10 ⁻¹¹	154	HLAB*1302	2 x 10 ⁻¹⁶
140	rs10573	3 x 10 ⁻¹¹	155	rs61444472	2 x 10 ⁻¹⁷
141	rs9271066	2 x 10 ⁻¹¹	156	rs17193507	2 x 10 ⁻¹⁸
142	rs3130618	2 x 10 ⁻¹¹	157	rs12524487	7 x 10 ⁻²⁰
143	rs62392216	1 x 10 ⁻¹¹	158	HLAB*5201	3 x 10 ⁻²⁰
144	HLAB*1501	1 x 10 ⁻¹¹	159	HLA-B*1302	3 x 10 ⁻²⁵
145	rs1265067	8 x 10 ⁻¹²	160	rs17193507	7 x 10 ⁻³⁰
146	rs2099684	7 x 10 ⁻¹²	161	rs9262437	5 x 10 ⁻³¹
147	rs10919543	6 x 10 ⁻¹²	162	rs117298325	4 x 10 ⁻³⁴
148	rs2836883	1 x 10 ⁻¹²	163	HLA-B*5201	4 x 10 ⁻³⁶
149	rs2322599	3 x 10 ⁻¹³	164	rs12524487	6 x 10 ⁻³⁸
150	rs12524487	3 x 10 ⁻¹⁵	165	rs2844678	2 x 10 ⁻⁴²
151	HLA-B*1501	1 x 10 ⁻¹⁵	166	rs2844678	6 x 10 ⁻⁴⁷

Lampiran 7. Hasil Analisis Basis Data HaploReg_Versi 4.2

HaploReg v4.2

HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci. Using LD information from the 1000 Genomes Project, linked SNPs and small indels can be visualized along with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. HaploReg is designed for researchers developing mechanistic hypotheses of the impact of non-coding variants on clinical phenotypes and normal variation.

Update 2015.11.05: Version 4.1 GWAS and eQTL have been updated; a simpler pruning strategy is applied when combining GWAS; and links out to other NHGRI/EBI GWAS hits and GRASP QTL hits are provided.

Update 2015.06.15: Version 4.0 now includes many recent eQTL results including the GTEx pilot, four different options for defining enhancers using Roadmap Epigenomics data, and a complete set of source files for download and local analysis. Older versions available [v3](#), [v2](#), [v1](#).

Update 2023.04.29: Version 4.2 released. Parts of the site may still not work correctly - please email haploreg (at) mit.edu for support.

[Build Query](#)
[Set Options](#)
[Documentation](#)

Use one of the three methods below to enter a set of variants. If an r^2 threshold is specified (see the Set Options tab), results for each variant will be shown in a separate table along with other variants in LD. If r^2 is set to NA, only queried variants will be shown, together in one table.

Query (comma-delimited list of rsIDs OR a single region as chrN:start-end)

or, upload a text file (one refSNP ID per line): Choose File No file chosen

or, select a GWAS:

Submit

Query SNP: **rs3130610** and variants with $r^2 \geq 0.8$

chr	pos (hg38)	LD (r ²)	LD (D')	variant	Ref	Alt	AFR	AMR	ASN	EUR	SHP	Promoter	Enhancer	DNase	Proteins	Motifs	NHGRI/EBI	GRASP QTL	Selected eQTL	GENCODE	dbSNP	
							freq	freq	freq	freq	freq	histone marks	histone marks	seq	bound	changed	hits	hits	hits	genes	func annot	
6	31610246	0.85	0.2	rs3130621	T	C	0.22	0.08	0.06	0.15		5 tissues	5 tissues			9 altered motifs			48 hits	1-453 3' of PRRC2A	intronic	
6	31612447	0.85	0.94	rs3131665	C	G	0.22	0.09	0.06	0.15		5 tissues	5 tissues			9 altered motifs			45 hits	PRRC2A	intronic	
6	316124031	0.87	0.94	rs3130670	A	G	0.22	0.09	0.06	0.15		5 tissues	5 tissues					1 hit	50 hits	PRRC2A	intronic	
6	316124747	0.87	0.94	rs3130622	G	C	0.22	0.08	0.06	0.15		BLD	BLD					1 hit	50 hits	PRRC2A	intronic	
6	316124859	0.87	0.94	rs3131564	C	T	0.22	0.08	0.06	0.15		BLD	BLD						48 hits	PRRC2A	intronic	
6	316130988	0.86	0.93	rs3130624	A	G	0.24	0.09	0.06	0.15		IPSC, SKIN, MUS	IPSC, SKIN, MUS	BLD		POL24H8			46 hits	PRRC2A	intronic	
6	316130712	0.86	0.93	rs3130626	A	G	0.22	0.08	0.06	0.15		BRST, SKIN, LIV	BRST, SKIN, LIV	POL24H8, POL28				1 hit	54 hits	PRRC2A	synonymous	
6	316133043	0.86	0.93	rs2236152	A	G	0.22	0.08	0.06	0.15		SKIN, LIV	SKIN, LIV			9 altered motifs			56 hits	PRRC2A	intronic	
6	316133074	0.86	0.93	rs3130627	G	T	0.22	0.08	0.06	0.15		4 tissues	4 tissues						48 hits	PRRC2A	intronic	
6	316134066	0.85	0.93	rs3131563	T	C	0.23	0.08	0.06	0.15		SKIN, LIV	SKIN, LIV			9 altered motifs	1 hit	44 hits	56 hits	PRRC2A	intronic	
6	316135993	0.87	0.94	rs113229	A	G	0.23	0.08	0.06	0.15		SKIN, LIV	SKIN, LIV			AP-3, EN-1, G300		1 hit	48 hits	PRRC2A	synonymous	
6	316136814	0.87	0.94	rs139863	C	T	0.23	0.08	0.06	0.15		SKIN, LIV	SKIN, LIV			11 altered motifs		1 hit	50 hits	PRRC2A	intronic	
6	316138621	0.88	0.94	rs1330446	C	G	0.23	0.08	0.06	0.15		SKIN, MUS	SKIN, MUS			Myo2v			48 hits	400bp 3' of BAG6	intronic	
6	316141686	0.88	0.94	rs5875320	C	CAAA	0.23	0.08	0.06	0.15		4 tissues	4 tissues			CDP			7 hits	BAG6	5' UTR	
6	316141686	0.88	0.94	rs3130629	T	C	0.25	0.09	0.06	0.15		SKIN, LIV, BRN	SKIN, LIV, BRN			MYO1		1 hit	54 hits	BAG6	intronic	
6	316142702	0.95	0.98	rs3130647	C	T	0.23	0.08	0.06	0.15		SKIN, LIV	SKIN, LIV			PL1, JKRRA, STAT			54 hits	BAG6	intronic	
6	316151796	0.87	0.90	rs3111763	A	G	0.23	0.08	0.06	0.15		SKIN, LIV	SKIN, LIV			5 altered motifs		30 hits	54 hits	BAG6	intronic	
6	316153191	0.99	1	rs3117592	G	A	0.23	0.08	0.06	0.15		BRST	BRST			AP-3, EN-1, G300			48 hits	GRANK1	intronic	
6	316164357	1	1	rs3130610	A	G	0.23	0.08	0.06	0.15		BRST	BRST			10 tissues		2 hits	43 hits	54 hits	GRANK1	intronic
6	31605719	0.99	1	rs1117273	C	T	0.23	0.09	0.06	0.15		BRST	BRST			53 tissues	23 bound proteins		53 hits	GRANK1	5' UTR	

HaploReg v4.2

HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci. Using LD information from the 1000 Genomes Project, linked SNPs and small indels can be visualized along with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. HaploReg is designed for researchers developing mechanistic hypotheses of the impact of non-coding variants on clinical phenotypes and normal variation.

Update 2015.11.05: Version 4.1 GWAS and eQTL have been updated; a simpler pruning strategy is applied when combining GWAS; and links out to other NHGRI/EBI GWAS hits and GRASP QTL hits are provided.

Update 2015.06.15: Version 4.0 now includes many recent eQTL results including the GTEx pilot, four different options for defining enhancers using Roadmap Epigenomics data, and a complete set of source files for download and local analysis. Older versions available [v3](#), [v2](#), [v1](#).

Update 2023.04.29: Version 4.2 released. Parts of the site may still not work correctly - please email haploreg (at) mit.edu for support.

[Build Query](#)
[Set Options](#)
[Documentation](#)

Use one of the three methods below to enter a set of variants. If an r^2 threshold is specified (see the Set Options tab), results for each variant will be shown in a separate table along with other variants in LD. If r^2 is set to NA, only queried variants will be shown, together in one table.

Query (comma-delimited list of rsIDs OR a single region as chrN:start-end)

or, upload a text file (one refSNP ID per line): Choose File No file chosen

or, select a GWAS:

Submit

HaploReg v4.2



HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci. Using LD information from the 1000 Genomes Project, linked SNPs and small indels can be visualized along with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. HaploReg is designed for researchers developing mechanistic hypotheses of the impact of non-coding variants on clinical phenotypes and normal variation.

Update 2015.11.05: Version 4.1 GWAS and eQTL have been updated; a simpler pruning strategy is applied when combining GWAS; and links out to other NHGRI/EBI GWAS hits and GRASP QTL hits are provided.

Update 2015.09.15: Version 4.0 now includes many recent eQTL results including the GTEx pilot, four different options for defining enhancers using Roadmap Epigenomics data, and a complete set of source files for download and local analysis. Older versions available [v3](#), [v2](#), [v1](#).

Update 2022.04.28: Version 4.2 released. Parts of the site may still not work correctly - please email haploreg (at) mit.edu for support.

[Build Query](#) [Set Options](#) [Documentation](#)

Use one of the three methods below to enter a set of variants. If an r^2 threshold is specified (see the Set Options tab), results for each variant will be shown in a separate table along with other variants in LD. If r^2 is set to NA, only queried variants will be shown, together in one table.

Query (comma-delimited list of rsIDs OR a single region as chrN start-end):

or, upload a text file (one reFSNP ID per line):

or, select a GWAS:

Query SNP: **rs9267532** and variants with $r^2 \geq 0.8$

chr	pos (hg38)	LD (r ²)	LD (D)	variant	Ref	Alt	AFR freq	AMR freq	ASN freq	EUR freq	SiftS cons	Promoter histone marks	Enhancer histone marks	DNAse	Proteins bound	Motifs changed	NHGRI/EBI GWAS hits	GRASP QTL hits	Selected eQTL hits	GENCODE genes	dbSNP func annot
6	31640105	0.84	0.52	rs9267532	T	C	0.08	0.05	0.06	0.07			10 tissues	MUS		AP-1		9 hits	9 hits	BAO6	intronic
6	31600793	0.94	1	rs9267532	A	C	0.18	0.05	0.06	0.07		10 tissues	GR	8 tissues	POLR2L1	Fara GGNFHDAG2	1 hit	17 hits	CSNK2B	intronic	
6	31671552	0.94	1	rs9267532	G	A	0.19	0.05	0.06	0.07		10 tissues	GRN			GRN, GRN	4 hits	17 hits	LY6G5B	intronic	
6	31672200	1	1	rs9267532	C	T	0.16	0.05	0.06	0.07		10 tissues				BCL	2 hits	16 hits	LY6G5D	missense	
6	31676883	0.92	1	rs9267532	A	G	0.19	0.05	0.06	0.07		10 tissues	FAT, BLD, LUNG	BLD		EWSR1-FUT, Pw102, Znf143	1 hit	17 hits	LY6G5C	3'-UTR	
6	31678145	0.92	1	rs9267532	C	T	0.19	0.05	0.06	0.07		10 tissues	BLD, THYM	BLD		CHOP, CEPB, HNF1A, HNF1E2	1 hit	17 hits	LY6G5C	intronic	
6	31678880	0.92	1	rs9267532	T	C	0.19	0.05	0.06	0.07		10 tissues	BLD				1 hit	17 hits	LY6G5C	intronic	
6	31681372	0.92	1	rs9267532	C	G	0.19	0.05	0.06	0.07		10 tissues	BRN, BLD, LIV	24 tissues	4 bound proteins			19 hits	LY6G5C	intronic	
6	31687661	0.92	1	rs9267532	G	A	0.16	0.05	0.06	0.07		10 tissues			CTCF			1 hit	15 hits	ABHD16A	synonymous
6	31698829	0.92	1	rs9267532	C	T	0.19	0.05	0.06	0.07		10 tissues	BLD			HEN1, Pax5		19 hits	ABHD16A	intronic	
6	31699116	0.92	1	rs9267532	C	G	0.19	0.05	0.06	0.07		10 tissues	BLD, LIV			BRN, p53		19 hits	ABHD16A	intronic	
6	31700771	0.92	1	rs9267532	T	A	0.19	0.05	0.06	0.07		10 tissues	BLD			FOXK1, FOXK2	6 altered motifs	19 hits	ABHD16A	intronic	
6	31704192	0.9	0.98	rs9267532	G	A	0.19	0.06	0.06	0.07		10 tissues	10 tissues	4 tissues	CEBPB, JUNB	15 altered motifs	17 hits	LY6G5E	intronic		
6	31720423	0.8	0.9	rs9267532	C	T	0.19	0.07	0.06	0.07		10 tissues	5 tissues	7 tissues		6 altered motifs	5 hits	12 hits	CSN25	intronic	
6	31732880	0.8	0.9	rs9267532	G	T	0.26	0.08	0.06	0.07		10 tissues	8 tissues			IL-1	6 hits	8 hits	CLIC1	intronic	
6	31749919	0.8	0.9	rs9267532	A	G	0.26	0.07	0.06	0.07		10 tissues	BLD, BONE	DI	FOXK1, JUNB, GATA3	Brachyury, Ets1	14 hits	14 hits	MSH5	intronic	

HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci. Using LD information from the 1000 Genomes Project, linked SNPs and small indels can be visualized along with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. HaploReg is designed for researchers developing mechanistic hypotheses of the impact of non-coding variants on clinical phenotypes and normal variation.

Update 2015.11.05: Version 4.1 GWAS and eQTL have been updated; a simpler pruning strategy is applied when combining GWAS; and links out to other NHGRI/EBI GWAS hits and GRASP QTL hits are provided.

Update 2015.09.15: Version 4.0 now includes many recent eQTL results including the GTEx pilot, four different options for defining enhancers using Roadmap Epigenomics data, and a complete set of source files for download and local analysis. Older versions available [v3](#), [v2](#), [v1](#).

Update 2022.04.28: Version 4.2 released. Parts of the site may still not work correctly - please email haploreg (at) mit.edu for support.

[Build Query](#) [Set Options](#) [Documentation](#)

Use one of the three methods below to enter a set of variants. If an r^2 threshold is specified (see the Set Options tab), results for each variant will be shown in a separate table along with other variants in LD. If r^2 is set to NA, only queried variants will be shown, together in one table.

Query (comma-delimited list of rsIDs OR a single region as chrN start-end):

or, upload a text file (one reFSNP ID per line):

or, select a GWAS:

Query SNP: **rs10885** and variants with $r^2 \geq 0.8$

Submit																							
Query SNP rs10885 and variants with r ² >= 0.8																							
chr	pos (hg38)	LD	LD	variant	Ref	Alt	AFR	AMR	ASN	EUR	SiftS	Promoter	Enhancer	DNAse	Proteins	Motifs	NHGRI/EBI	GRASP	QTL	Selected	GENCODE	dbSNP	
							freq	freq	freq	freq	cons	histone marks	histone marks		bound	changed	GWAS hits	hits	hits	eQTL	genes	func annot	
6	31614240	0.87	0.98	rs1324261	G	C	0.22	0.09	0.09	0.10		10 tissues	10 tissues			7 altered motifs			49 hits	500bp 3' of APT1			
6	31619305	0.98	0.99	rs1324261	T	C	0.22	0.08	0.09	0.15		10 tissues	10 tissues			5 altered motifs			49 hits	1 kb 5' of PRRC2A			
6	31621487	0.98	1	rs1324261	C	G	0.22	0.09	0.09	0.15		10 tissues	10 tissues			5 altered motifs			45 hits		PRRC2A	intronic	
6	31624031	1	1	rs1324261	A	G	0.22	0.08	0.09	0.15		10 tissues	10 tissues			5 altered motifs			1 hit	50 hits	PRRC2A	intronic	
6	31624747	1	1	rs1324261	G	C	0.22	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	50 hits	PRRC2A	intronic	
6	31624859	1	1	rs1324261	C	T	0.22	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	50 hits	PRRC2A	intronic	
6	31629623	0.92	0.98	rs1324261	C	T	0.24	0.08	0.09	0.15		10 tissues	10 tissues						39 hits	50 hits	PRRC2A	intronic	
6	31630980	0.90	1	rs1324261	A	G	0.24	0.09	0.09	0.15		10 tissues	10 tissues						46 hits		PRRC2A	intronic	
6	31630712	0.90	1	rs1324261	A	G	0.22	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	56 hits	PRRC2A	synonymous	
6	31633043	0.90	1	rs1324261	A	G	0.22	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	56 hits	PRRC2A	intronic	
6	31633074	0.90	1	rs1324261	G	T	0.22	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	56 hits	PRRC2A	intronic	
6	31634065	0.98	0.99	rs1324261	T	C	0.23	0.08	0.09	0.15		10 tissues	10 tissues						6 altered motifs	1 hit	44 hits	PRRC2A	intronic
6	31635983	1	1	rs1324261	A	G	0.23	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	46 hits	PRRC2A	intronic	
6	31636114	1	1	rs1324261	C	T	0.23	0.08	0.09	0.15		10 tissues	10 tissues						1 hit	50 hits	PRRC2A	missense	
6	31638821	0.99	1	rs1324261	C	G	0.23	0.08	0.09	0.15		10 tissues	10 tissues						43 hits	400bp 3' of BAO6			
6	31638960	0.87	1	rs19920858	AAAAAC	A	0.22	0.08	0.09	0.13		10 tissues	10 tissues						65 hits	127bp 3' of BAO6			
6	31641895	0.96	1	rs3975328	C	CAAAAG	0.23	0.08	0.09	0.15		10 tissues	10 tissues						7 hits		BAO6	3'-UTR	
6	31642762	0.95	0.98	rs1324261	T	C	0.25	0.09	0.09	0.15		10 tissues	10 tissues						1 hit	54 hits	BAO6	intronic	
6	31642762	0.92	0.98	rs1324261	C	T	0.23	0.08	0.09	0.15		10 tissues	10 tissues						56 hits		BAO6	intronic	
6	31651769	0.9	0.95	rs1324261	A	G	0.23	0.08	0.09	0.15		10 tissues	10 tissues						39 hits	56 hits	BAO6	intronic	
6	31651769	0.88	0.94	rs1324261	A	G	0.23	0.08	0.09	0.15		10 tissues	10 tissues						56 hits		GBAN1	intronic	
6	31654387	0.87	0.94	rs1324261	A	G	0.23	0.08	0.09	0.15		10 tissues	10 tissues						56 hits		GBAN1	intronic	
6	31655819	0.88	0.94	rs1324261	G	T	0.23	0.08	0.09	0.15		10 tissues	10 tissues						2 hits	43 hits	56 hits	GBAN1	5'-UTR

HaploReg v4.2



HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci. Using LD information from the 1000 Genomes Project, linked SNPs and small indels can be visualized along with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. HaploReg is designed for researchers developing mechanistic hypotheses of the impact of non-coding variants on clinical phenotypes and normal variation.

Update 2018.11.05: Version 4.1 GWAS and eQTL have been updated, a simpler pruning strategy is applied when combining GWAS, and links out to other NHGRI/EBI GWAS hits and GRASP QTL hits are provided.

Update 2018.09.18: **Version 4.0** now includes many recent eQTL results including the GTEx pilot, four different options for defining enhancers using Roadmap Epigenomics data, and a complete set of source files for download and local analysis. Older versions available: [v3](#), [v2](#), [v1](#).

Update 2023.04.28: Version 4.2 released. Parts of the site may still not work correctly - please email haploreg@mit.edu for support.

[Build Query](#) [Set Options](#) [Documentation](#)

Use one of the three methods below to enter a set of variants. If an r^2 threshold is specified (see the Set Options tab), results for each variant will be shown in a separate table along with other variants in LD. If r^2 is set to NA, only queried variants will be shown, together in one table.

Query (comma-delimited list of rsIDs OR a single region as chr1:257547

or, upload a text file (one refSNP ID per line):

Choose File No file chosen

or, select a GWAS:

Submit

Query SNP: **rs9267547** and variants with $r^2 \geq 0.8$

chr	pos (hg38)	LD (r ²)	variant	Ref	Alt	AFR freq	AMR freq	ASN freq	EUR freq	S/Phy cons	Promoter histone marks	Enhancer histone marks	DNAse	Proteins bound	Motifs changed	NHGRI/EBI GWAS hits	GRASP QTL hits	Selected eQTL hits	GENCODE genes	dbSNP func anno	
6	31705959	1	rs9267546	G	A	0.30	0.12	0.08	0.09	0.09	BLD	BLD	BLD		None			13 hits	32 hits	LYGG6F	
6	31707124	1	rs9267547	G	A	0.30	0.12	0.09	0.09	0.09	BLD	BLD	BLD		None		2 hits	11 hits	LYGG6F	missense	
6	31708200	1	rs9267548	C	T	0.30	0.12	0.08	0.09	0.09				ANKR,Ami,Amtp300			0 hits		LYGG6F	incomplete	

HaploReg v4.2



HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci. Using LD information from the 1000 Genomes Project, linked SNPs and small indels can be visualized along with chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies. HaploReg is designed for researchers developing mechanistic hypotheses of the impact of non-coding variants on clinical phenotypes and normal variation.

Update 2018.11.05: Version 4.1 GWAS and eQTL have been updated, a simpler pruning strategy is applied when combining GWAS, and links out to other NHGRI/EBI GWAS hits and GRASP QTL hits are provided.

Update 2018.09.18: **Version 4.0** now includes many recent eQTL results including the GTEx pilot, four different options for defining enhancers using Roadmap Epigenomics data, and a complete set of source files for download and local analysis. Older versions available: [v3](#), [v2](#), [v1](#).

Update 2023.04.28: Version 4.2 released. Parts of the site may still not work correctly - please email haploreg@mit.edu for support.

[Build Query](#) [Set Options](#) [Documentation](#)

Use one of the three methods below to enter a set of variants. If an r^2 threshold is specified (see the Set Options tab), results for each variant will be shown in a separate table along with other variants in LD. If r^2 is set to NA, only queried variants will be shown, together in one table.

Query (comma-delimited list of rsIDs OR a single region as chr1:4547951

or, upload a text file (one refSNP ID per line):

Choose File No file chosen

or, select a GWAS:

Submit

Query SNP: **rs45479291** and variants with $r^2 \geq 0.8$

chr	pos (hg38)	LD (r ²)	variant	Ref	Alt	AFR	AMR	ASN	EUR	S/Phy	Promoter	Enhancer	DNAse	Proteins bound	Motifs changed	NHGRI/EBI	GRASP	QTL hits	Selected eQTL hits	GENCODE genes	dbSNP	Func annotation
6	26962685	0.82	rs2096804	T	C	0.01	0.03	0.14	0.06						15 altered motifs			38 hits	1200 hits of ZFP57			
6	26962683	0.82	rs4607427	G	A	0.00	0.03	0.15	0.06						BCL11C,YY1			38 hits	1300 hits of ZFP57			
6	26962685	0.82	rs2096804	A	G	0.00	0.03	0.14	0.06						4 altered motifs			38 hits	1300 hits of ZFP57			
6	26962625	0.82	rs2076896	G	A	0.00	0.03	0.14	0.06						YY1			38 hits	1300 hits of ZFP57			
6	26963050	0.82	rs22381757	G	T	0.00	0.03	0.14	0.06						20 altered motifs			38 hits	1300 hits of ZFP57			
6	26964992	0.82	rs62381788	C	T	0.00	0.03	0.14	0.06			ESC, IPSC, BLD	BLD		4 altered motifs			38 hits	1400 hits of ZFP57			
6	26965140	0.82	rs140213817	C	CA	0.00	0.03	0.14	0.06			ESC, IPSC, BLD			EWRI1-FL11 REP-Juapla			8 hits	1400 hits of ZFP57			
6	26965560	0.82	rs55152973	C	T	0.00	0.03	0.14	0.06			ESC, IPSC			E2A,TRX,ZEB1			38 hits	1500 hits of ZFP57			
6	26967206	0.82	rs22321779	C	T	0.00	0.03	0.14	0.06			IPSC			Nanog			38 hits	1600 hits of ZFP57			
6	26970221	0.82	rs52628224	C	G	0.00	0.03	0.14	0.06						5 altered motifs			38 hits	2100 hits of HLA-F			
6	26970542	0.82	rs17184861	C	T	0.00	0.03	0.15	0.06						NERF1a			38 hits	1800 hits of HLA-F			
6	26970829	0.82	rs22167185	C	T	0.00	0.03	0.14	0.06			4 tissues	48 tissues	8 bound proteins	9 altered motifs			38 hits	1700 hits of HLA-F			
6	26970951	0.82	rs22347788	C	T	0.00	0.03	0.14	0.06						13 tissues			38 hits	1600 hits of HLA-F			
6	26970968	0.82	rs115265518	T	C	0.00	0.03	0.14	0.06			BLN, HRT	5 tissues		6 altered motifs			40 hits	1300 hits of HLA-F			
6	26971032	0.82	rs115951495	T	C	0.00	0.03	0.14	0.06			BLD, THYM, SPLN	BLD		SDX5,STAT2,NF2B3			40 hits	1300 hits of HLA-F			
6	26971297	0.86	rs114488801	C	T	0.00	0.03	0.14	0.06			BLD	BLD	ERN	BLD			9 hits of HLA-F				
6	26971492	0.86	rs17184892	G	A	0.00	0.03	0.14	0.06			BLD			4 altered motifs			40 hits	9 hits of HLA-F			
6	26971492	0.86	rs17184892	A	G	0.00	0.03	0.14	0.06			BLD			4 altered motifs			40 hits	9 hits of HLA-F			
6	26972226	0.91	rs20944923	C	T	0.00	0.03	0.14	0.06			BLN, HRT	33 tissues	8 bound proteins	9 altered motifs			40 hits	HLA-F			intronic
6	26972949	0.91	rs11425231	G	T	0.00	0.03	0.14	0.06			31 tissues	BLD, BLD, BLD	POL24H8	DBP,NF-kappaB			40 hits	HLA-F			intronic
6	26972956	0.91	rs5231381	A	G	0.00	0.03	0.14	0.06			BLD, HRT, SPLN	POL24H8		6 altered motifs			40 hits	HLA-F			intronic
6	269728031	0.91	rs52672647	A	G	0.00	0.03	0.14	0.06			BLD, SKIN, SPLN	BLD, BLD, BLD	POL24H8	CTCF,Rad21,Smad3			46 hits	HLA-F			intronic
6	269729643	0.91	rs2381819	A	G	0.00	0.03	0.14	0.06			BLD			10 altered motifs			38 hits	HLA-F			intronic
6	26973277	0.95	rs2381821	T	C	0.01	0.04	0.13	0.06						TBX5			38 hits	HLA-F			intronic
6	269734797	0.95	rs2381822	T	C	0.00	0.03	0.14	0.06			BLN, BLD, SKIN	7 tissues	PUSC26	BCL11C,YY1			38 hits	HLA-F			intronic
6	269735748	0.97	rs2381823	T	C	0.00	0.03	0.14	0.06			8 tissues			4 altered motifs			38 hits	HLA-F-AS1			intronic
6	269740266	0.97	rs2381826	C	G	0.00	0.03	0.14	0.06			BLN, SKIN			BATF1,VDR			38 hits	HLA-F-AS1			intronic
6	269740745	0.95	rs4141386	C	T	0.00	0.03	0.14	0.06			SKIN			ERalpha-2			38 hits	HLA-F-AS1			intronic
6	269743003	0.95	rs29762521	C	T	0.01	0.03	0.14	0.06			SKIN			5 altered motifs			38 hits	HLA-F-AS1			intronic
6	269747071	0.95	rs62391835	G	A	0.00	0.03	0.14	0.06			15 tissues	15 tissues	7 tissues	E2F1,Smc3,20,Zfp413			38 hits	65 hits of HLA-F-AS1			
6	269751178	0.95	rs56840468	G	A	0.00	0.03	0.14	0.06			BLN, HRT, SPLN			FEZF1,FXS,Zfp413			38 hits	7500 hits of vRNA			
6	269755583	0.95	rs2381842	T	C	0.00	0.03	0.14	0.06			IPSC	8 tissues	ESC,IPSC	BCL11			38 hits	5 hits of vRNA			
6	269756737	0.95	rs2381843	A	T	0.00	0.03	0.14	0.06			ESC, IPSC			SEF-1			38 hits	6 hits of vRNA			
6	269760844	0.95	rs2381844	T	C	0.00	0.03	0.14	0.06						22 altered motifs			38 hits	1000 hits of vRNA			
6	269764169	0.95	rs56279531	T	C	0.00	0.03	0.14	0.06			13 tissues	BRETVAS		20 altered motifs			38 hits	1400 hits of vRNA			
6	269770265	0.95	rs23818775	T	C	0.00	0.03	0.15	0.06			SKIN	SKIN		Foxd1			38 hits	2800 hits of vRNA			
6	269771223	0.95	rs3888722	C	G	0.00	0.03	0.15	0.06			IPSC, SKIN						40 hits	2100 hits of vRNA			
6	269772247	0.95	rs23818556	G	A	0.00	0.03	0.15	0.06						4 altered motifs			38 hits	2200 hits of vRNA			
6	269772771	0.95	rs23818551	G	A	0.00	0.03	0.15	0.06			ESDR			CERPB,VDR			38 hits	2300 hits of vRNA			
6	269773758	0.95	rs56352172	T	C	0.00	0.03	0.15	0.06						5 altered motifs			38 hits	2300 hits of vRNA			
6	269775565	0.95	rs23818568	T	C	0.00	0.03	0.15	0.06						Exon1,ORF1,ORF2			38 hits	2500 hits of vRNA			
6	269776358	0.95	rs148501534	A	C	0.00	0.03	0.15	0.06						9 altered motifs			8 hits	2800 hits of vRNA			
6	269777434	0.93	rs23818479	A	G	0.00	0.03	0.15	0.06			ESC	SKIN,SKIN		6 altered motifs			38 hits	2700 hits of vRNA			
6	269780732	0.95	rs136919383	C	T	0.00	0.03	0.15	0.06						JRE,AREB-1			46 hits	5000 hits of vRNA			
6	269785906	1	rs59230898	A	G	0.00	0.03	0.15	0.06						13 altered motifs			38 hits	3500 hits of vRNA			
6	269786054	1	rs27362831	C	A	0.00	0.03	0.15	0.06			SKIN		USP1			38 hits	3600 hits of vRNA				
6	269786591	0.91	rs118487225	T	G	0.00	0.04	0.15	0.06			IPSC			14 altered motifs			44 hits	3800 hits of vRNA			
6	269786903	0.89	rs23818172	C	T	0.01	0.05	0.15	0.06						Zfp187			23 hits	3800 hits of HLA-G			
6	269787252	1	rs45479291	G	C	0.00	0.03	0.15	0.06			20 tissues	BLN, HRT	10 tissues	POLY-YY1,RPKS			38 hits	3500 hits of HLA-G			missense
6	269787259	1	rs45480963	G	A	0.00	0.03	0.15	0.06			20 tissues	ESDR, SKIN, HRT	10 tissues	NR3FRCB-1			38 hits	3500 hits of HLA-G			intronic
6	269789491	1	rs18685752	C	T	0.00	0.03	0.15	0.06			SKIN			Hes613			46 hits	3300 hits of HLA-G			intronic
6	269789492	1	rs52719444	A	T	0.00	0.03	0.15	0.06			FAT, SKIN	SKIN		5 altered motifs			38 hits	3300 hits of HLA-G			intronic

Lampiran 8. Hasil Analisis Basis Data GTEx Portal

Significant Single-Tissue eQTLs for GPANK1 (ENSG00000204438.11) in all tissues
Data Source: GTEx Analysis Release V10 (dbGaP Accession phs000424.v10.p2)

Copy	CSV	Search: rs3130618					Show	10	entries
Gencode Id	Gene Symbol	Variant Id	SNP	P-Value	NES	Tissue	Actions		
ENSG00000204438.11	GPANK1	chr6_31664357_C_A_b38	rs3130618 dbSNP	3.8e-8	-0.18	Nerve - Tibial	eQTL violin plot		
ENSG00000204438.11	GPANK1	chr6_31664357_C_A_b38	rs3130618 dbSNP	2.6e-7	-0.17	Artery - Tibial	eQTL violin plot		
ENSG00000204438.11	GPANK1	chr6_31664357_C_A_b38	rs3130618 dbSNP	0.000020	-0.14	Esophagus - Muscularis	eQTL violin plot		
ENSG00000204438.11	GPANK1	chr6_31664357_C_A_b38	rs3130618 dbSNP	0.000021	-0.15	Thyroid	eQTL violin plot		
ENSG00000204438.11	GPANK1	chr6_31664357_C_A_b38	rs3130618 dbSNP	0.00021	-0.15	Artery - Aorta	eQTL violin plot		

Significant Single-Tissue eQTLs for CCHCR1 (ENSG00000204536.15) in all tissues
Data Source: GTEx Analysis Release V10 (dbGaP Accession phs000424.v10.p2)

Copy	CSV	Search: rs1576				Show 10	entries
Gencode Id	Gene Symbol	Variant Id	SNP	P-Value	NES	Tissue	Actions
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	5.3e-88	0.55	Adipose - Subcutaneous	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	5.0e-81	0.51	Nerve - Tibial	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	1.5e-77	0.44	Colon - Transverse	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	1.7e-75	0.50	Thyroid	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	1.1e-74	0.47	Adipose - Visceral (Omentum)	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	2.2e-72	0.54	Lung	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	6.6e-65	0.44	Breast - Mammary Tissue	eQTL violin plot
ENSG00000204536.15	CCHCR1	chr6_31142614_G_C_b38	rs1576 dbSNP	9.2e-58	0.39	Whole Blood	eQTL violin plot

Significant Single-Tissue eQTLs for LY6G5B (ENSG00000240053.8) in all tissues
Data Source: GTEx Analysis Release V10 (dbGaP Accession phs000424.v10.p2)

Copy	CSV					Search: rs9267532	Show 10	entries
Gencode Id	Gene Symbol	Variant Id	SNP	P-Value	NES	Tissue	Actions	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	1.8e-10	-0.23	Muscle - Skeletal	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	5.5e-9	-0.21	Thyroid	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	1.1e-7	-0.15	Skin - Sun Exposed (Lower leg)	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	1.2e-7	-0.19	Nerve - Tibial	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	2.4e-7	-0.17	Adipose - Subcutaneous	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	2.4e-7	-0.25	Cells - Cultured Fibroblasts	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	4.4e-7	-0.26	Colon - Transverse	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	6.1e-7	-0.21	Esophagus - Mucosa	eQTL violin plot	
ENSG00000240053.8	LY6G5B	chr6_31672202_C_T_b38	rs9267532 dbSNP	0.0000036	-0.13	Whole Blood	eQTL violin plot	

Significant Single-Tissue eQTLs for PRRC2A (ENSG00000204469.13) in all tissues
 Data Source: GTEx Analysis Release V10 (dbGaP Accession phs000424.v10.p2)

Copy		CSV		Search: rs10886			Show 10 entries	
Gencode Id	Gene Symbol	Variant Id	SNP	P-Value	NES	Tissue	Actions	
ENSG00000204469.13	PRRC2A	chr6_31636814_C_T_b38	rs10886 dbSNP	0.00013	-0.063	Whole Blood	eQTL violin plot	
ENSG00000204469.13	PRRC2A	chr6_31636814_C_T_b38	rs10886 dbSNP	0.00033	-0.11	Muscle - Skeletal	eQTL violin plot	

Significant Single-Tissue eQTLs for LY6G6F (ENSG00000204424.10) in all tissues
 Data Source: GTEx Analysis Release V10 (dbGaP Accession phs000424.v10.p2)

Copy CSV		Search: rs9267547					Show 10 entries
Gencode Id	Gene Symbol	Variant Id	SNP	P-Value	NES	Tissue	Actions
ENSG00000204424.10	LY6G6F	chr6_31707724_G_A_b38	rs9267547 dbSNP	2.2e-7	-0.30	Testis	eQTL violin plot

Significant Single-Tissue eQTLs for HLA-V (ENSG00000181126.13) in all tissues
 Data Source: GTEx Analysis Release V10 (dbGaP Accession phs000424.v10.p2)

Copy	CSV	Search: rs45479291					Show 10	entries
Gencode Id	Gene Symbol	Variant Id	SNP	P-Value	NES	Tissue	Actions	
ENSG00000181126.13	HLA-V	chr6_29792252_G_C_b38	rs45479291 dbSNP	1.7e-9	0.54	Lung	eQTL violin plot	
ENSG00000181126.13	HLA-V	chr6_29792252_G_C_b38	rs45479291 dbSNP	0.00017	-0.70	Spleen	eQTL violin plot	

Lampiran 9. Hasil Analisis Basis Data *Ensembl Genome Browser*

rs3130618 SNP

This variant maps to 7 locations

Select a location:

Alleles

C/A/T

Location

This variant maps to 7 genomic locations. Please select a location in the box above.

Evidence status



Synonyms

This variant has 5 synonyms - [Show](#)

Genotyping chips

This variant has assays on 13 chips - [Show](#)

Original source


Variants (including SNPs and indels) imported from dbSNP (release 156) | [View in dbSNP](#)

About this variant

This variant has [2504 sample genotypes](#), is associated with [29 phenotypes](#) and is mentioned in [15 citations](#).

Population genetics

1000 Genomes Project Phase 3 allele frequencies



rs1576 SNP

This variant maps to 6 locations

Select a location:

Alleles

G/A/C

Location

This variant maps to 6 genomic locations. Please select a location in the box above.

Evidence status



Synonyms

This variant has 6 synonyms - [Show](#)

Genotyping chips

This variant has assays on 6 chips - [Show](#)

Original source


Variants (including SNPs and indels) imported from dbSNP (release 156) | [View in dbSNP](#)

About this variant

This variant has [2504 sample genotypes](#), is associated with [24 phenotypes](#) and is mentioned in [24 citations](#).

Population genetics

1000 Genomes Project Phase 3 allele frequencies



rs9267532 SNP

i This variant maps to 7 locations

Select a location: None selected

Go

Alleles

C/T

Location

This variant maps to 7 genomic locations. Please select a location in the box above.

Evidence status **i**



Synonyms

This variant has 4 synonyms - [Show](#)

Genotyping chips

This variant has assays on 13 chips - [Show](#)

Original source


Variants (including SNPs and indels) imported from dbSNP (release 156) | [View in dbSNP](#)

About this variant

This variant has [2504 sample genotypes](#), is associated with [21 phenotypes](#) and is mentioned in [5 citations](#).

Population genetics **i**

1000 Genomes Project Phase 3 allele frequencies



rs10885 SNP

i This variant maps to 7 locations

Select a location: None selected

Go

Alleles

C/T

Location

This variant maps to 7 genomic locations. Please select a location in the box above.

Evidence status **i**



Clinical significance **i**



HGVS names

This variant has 4 HGVS names - [Show](#)

Synonyms

This variant has 11 synonyms - [Show](#)

Genotyping chips

This variant has assays on 6 chips - [Show](#)

Original source


Variants (including SNPs and indels) imported from dbSNP (release 156) | [View in dbSNP](#)

About this variant

This variant has [2504 sample genotypes](#), is associated with [22 phenotypes](#) and is mentioned in [11 citations](#).

Population genetics **i**

1000 Genomes Project Phase 3 allele frequencies



rs9267547 SNP

This variant maps to 7 locations

Select a location: None selected

Go

Alleles

G/A

Location

This variant maps to 7 genomic locations. Please select a location in the box above.

Evidence status



Synonyms

This variant has 5 synonyms - [Show](#)

Genotyping chips

This variant has assays on 6 chips - [Show](#)

Original source


Variants (including SNPs and indels) imported from dbSNP (release 156) | [View in dbSNP](#)

About this variant

This variant has [2504 sample genotypes](#), is associated with [7 phenotypes](#) and is mentioned in [3 citations](#).

Population genetics

1000 Genomes Project Phase 3 allele frequencies



rs45479291 SNP

This variant maps to 8 locations

Select a location: None selected

Go

Alleles

G/C | MAF: 0.09 (C)

Location

This variant maps to 8 genomic locations. Please select a location in the box above.

Evidence status



Synonyms

Archive dbSNP [rs62394673](#), [rs117660460](#), [rs116058856](#)

Genotyping chips

This variant has assays on: Illumina_ExomeChip, Illumina_HumanOmni5, HumanCoreExome-12

Original source

Variants (including SNPs and indels) imported from dbSNP (release 156) | [View in dbSNP](#)

About this variant

This variant has predicted consequences for [1 regulatory feature](#), has [2504 sample genotypes](#), is associated with [8 phenotypes](#) and is mentioned in [1 citation](#).

Population genetics

1000 Genomes Project Phase 3 allele frequencies

